

AD_____

Award Number: DAMD17-98-1-8173

TITLE: Gene Painting as a Simple Method for Vaccinating Animals
Against Breast Cancer Micro-Metastases

PRINCIPAL INVESTIGATOR: De-chu Tang, Ph.D.

CONTRACTING ORGANIZATION: University of Alabama at Birmingham
Birmingham, Alabama 35294-0111

REPORT DATE: October 2001

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20020910 090

PII Redacted

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE October 2001	3. REPORT TYPE AND DATES COVERED Final (01 Oct 00 - 30 Sep 01)	
4. TITLE AND SUBTITLE Gene Painting as a Simple Method for Vaccinating Animals Against Breast Cancer Micro-Metastases			5. FUNDING NUMBERS DAMD17-98-1-8173	
6. AUTHOR(S) De-chu Tang, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Alabama at Birmingham Birmingham, Alabama 35294-0111 E-Mail: dctang@uab.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES Report contains color and an appendix in non-print form				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) We are developing a simple and effective method for the delivery of cancer vaccines by noninvasive vaccination onto the skin (NIVS) using a patch. The hypothesis is that a noninvasive vaccine patch can elicit specific immune responses to tumor-associated antigens with resultant eradication of limited numbers of tumor cells in animals with low tumor burden breast cancer. In these studies, we have elicited anti-CEA antibodies by topical application of an adenovirus vector encoding CEA. Furthermore, animals immunized by this novel vaccination modality were well protected against a mammary tumor cell line expressing CEA. When compared to other means of immunization including intramuscular injection of DNA and intranasal inoculation of adenovirus vectors, the skin-targeted vaccine patch appeared to be more protective in a disease setting, probably due to the immunocompetence of the outer layer of skin where antigens were expressed. We envision that patch-based vaccination may emerge as an important technique for the administration of vaccines because the procedure is simple, effective, economical, painless, and safe. It may also boost vaccine coverage due to patient comfort.				
14. SUBJECT TERMS vaccine, skin, adenovirus, breast, cancer				15. NUMBER OF PAGES 45
				16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

Table of Contents

Cover.....	1
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	5-7
Key Research Accomplishments.....	8
Reportable Outcomes.....	9-10
Conclusions.....	11
References.....	12-13
Appendices.....	14-45

INTRODUCTION

The induction or augmentation of tumor-specific immune responses providing protection against neoplastic disease is a promising approach for treating metastatic breast cancers. Genetic immunization potentially may present functional antigenic proteins to the host for recognition by all arms of the immune system, yet is able to delete pieces of tumor antigens that may have deleterious effects. We have demonstrated that the surface of the skin is a convenient and effective site for the inoculation of genetic vaccines. Since the outer layer of skin interfaces directly with the external environment and is in constant contact with innumerable pathogens, immunologic components for the elicitation of both humoral and cytotoxic cellular immune responses must be present along the skin border for counteracting undesirable infections. Evidence supporting the immunologic competence of the outer layer of skin includes: 1) Antigens expressed in the epidermis are more immunogenic than those expressed in the dermis (3, 13), and 2) genetic vaccines inoculated into the epidermis using a gene gun are more potent than those injected intramuscularly (5). Injection of vaccines underneath the epidermis as commonly practiced is likely to bypass an epidermis-associated immune surveillance zone along the border, resulting in insufficient or inappropriate immune responses. The large accessible area of the skin and its durability are other advantages for applying genetic vaccines to this tissue. The immunologic competence of the skin, the ease with which genes can be targeted to defined sites within the skin, the rapid turn-over of skin cells, and our finding that animals can be protected against tumor challenges by noninvasive vaccination onto the skin (NIVS), may allow for the development of a unique method for the administration of vaccines. In these studies, we have demonstrated that anti-CEA (carcinoembryonic antigen) antibodies could be elicited by adenovirus-based NIVS. Furthermore, animals immunized by a skin patch containing AdCMV-hcea (an adenovirus vector encoding human CEA) (16) were protected against challenges by a mammary tumor cell line expressing CEA. Results suggested that vaccination against metastatic breast cancers may be achieved by a noninvasive skin patch. This approach not only may boost vaccine coverage because the procedure requires no specially trained personnel and equipment, but also may be able to elicit potent antitumor immune responses because antigens are expressed in the outer layer of skin which is a very immunocompetent tissue.

BODY

Task 1. Construction of a target cell line.

The murine mammary tumor cell line JC derived from a female Balb/c mouse was obtained from ATCC. A CEA-expressing mammary tumor cell line JC-hcea was constructed by co-transfecting pGT37 (2) with pH β APr-1-neo (8) at a molar ratio of 10:1, followed by selecting transfectants in medium containing G418. G418-resistant clones containing the human CEA sequences were validated by PCR analysis.

Task 2. Construction of a new adenovirus vector with reduced immunogenicity as carriers for cancer vaccines.

Adenovirus vectors with all viral genes deleted (gutless adenovirus vectors) were developed using the Cre-loxP recombination system (11). These vectors not only accommodate large inserts, but also may allow repeated expression of antigens in animals due to their reduced immunogenicity (1). A gutless adenovirus vector system (*i.e.*, pRP1001, AdLC8cluc, and 293Cre4 cells) has been made available to us from the Merck Research Laboratories. However, a problem with the current gutless adenovirus system is the contamination of the viral stock by helper virus (11) because efficiency of the Cre-loxP recombination system for excising the packaging signal is not 100%. Our vector preparation contained substantial amounts of the AdLC8cluc helper virus during our preliminary studies. Although the vector/helper ratio may be improved after prolonged propagation in 294cre cells due to a selective disadvantage for the helper virus to be packaged, the procedure is time-consuming and the viral stock can hardly be helper-free. To this end, we are taking a novel approach for constructing helper-free gutless adenovirus vectors by co-transfecting pRP1001-based plasmids with a packaging signal (7)-free helper plasmid. To construct a helper plasmid without a packaging signal (AdEasy-hp), the left ITR (inverted terminal repeat) of adenovirus was amplified from the pShuttle plasmid (10) using two primers 5'-CGGGGATCGATGGCGCATCATCAATAATATACCTTATTT-3' and 5'-ATATCGATACAACATCCGCCTAAAACCGCGCG-3'. pAdEasy-hp was constructed by cloning the left ITR sequence into the unique Cla I site of the pAdEasy-1 plasmid which lacks the left ITR, packaging signal, and E1 region (10). When pRP1001-based plasmids are co-transfected with pAdEasy-hp into human 293 cells, the E1 function will be provided *in trans* by the host whereas all other adenoviral proteins may be produced by pAdEasy-hp. Because pAdEasy-hp contains two functional ITRs as the origin of replication, it may replicate as an autonomous replicon in 293 cells (9), and late gene transcripts may be terminated correctly after DNA synthesis. Since pAdEasy-hp does not contain a packaging signal, none of its DNA molecules can be packaged into infectious particles. pAdEasy-hp may thus support the production of helper-free gutless adenovirus vectors.

Task 3. Develop DNA-based gene painting schemes.

We are the first to have demonstrated that an immune response could be elicited by topical application of adenovirus recombinants (13, 16), DNA:adenovirus complexes (12), or DNA:liposome complexes (12). Others have shown that the immune system could also be activated to some extent following topical application of cholera toxin protein (6) or naked DNA (4). However, emerging evidence suggests that the adenovirus-based vector system is more promising than the DNA-based system as a carrier for skin-targeted noninvasive vaccines because antigen expression from an adenovirus vector is more efficient than DNA-mediated gene expression following topical application (12, 13). The problem of eliciting an anti-adenovirus immune response which may interfere with subsequent cycles of immunization following topical application of the E1/E3-defective adenovirus vector may readily be circumvented by booster applications (13) and/or the development of the helper-free gutless adenovirus vector system (Task 1).

Task 4. Vaccination of animals against mammary tumors by gene painting.

1. Elicitation of anti-CEA antibodies in mice. We have experience in immunizing animals with a noninvasive vaccine patch (12, 13, 16). **Figure 1** shows that antisera against CEA could be induced in mice by a vaccine patch containing AdCMV-hcea (an adenovirus vector encoding CEA) (16). Serum samples were collected from BALB/c mice that had been immunized by intramuscular injection of pGT37 DNA (a plasmid expression vector encoding human CEA) (2), intranasal inoculation of AdCMV-hcea, or noninvasive application of AdCMV-hcea onto abdominal skin using a skin patch. Evidence suggested that only a small fraction of topically applied vectors may be absorbed by the skin (13). **Figure 1** shows that absorption of vectors by unbroken skin could elicit anti-CEA antibodies at a higher titer than that achieved by intramuscular injection of a large dose of DNA, although intranasal inoculation of adenovirus vectors appeared to be more potent than NIVS in eliciting a humoral immune response probably due to more efficient gene transfer in the respiratory tract. Control animals including naïve mice and mice immunized by topical application of an irrelevant vector all failed to elicit anti-CEA.

2. Elicitation of a protective antitumor immune response by skin-targeted noninvasive vaccine patches. To test the efficacy of a noninvasive vaccine in a disease setting, mice were challenged by subcutaneous injection of 3×10^5 JC-hcea cells, then monitored daily for mortality. **Figure 2** depicts mice immunized by AdCMV-hcea-based noninvasive vaccine patches compared to groups which were immunized by intramuscular injection of pGT37 DNA, intranasal inoculation of AdCMV-hcea, topical application of an irrelevant vector AdCMV-PR8.ha, or received no vaccines. Mice immunized by topical application of AdCMV-hcea were afforded 100% protection from the challenge. Animals immunized by intranasal inoculation of AdCMV-hcea or intramuscular injection of pGT37 were also protected. In contrast, those that were immunized by an irrelevant vector or received no vaccines had the highest mortality rate and sustained significant weight loss before they either died, or slowly recovered. It is interesting to note that protection did not correlate with the titer of anti-CEA (**Figure 1**).

It is conceivable that a protective antitumor immune response may also involve cytotoxic T lymphocyte (CTL) responses that have not been measured in these studies.

3. In vivo cytotoxicity assay. To analyze the antitumor immune response in an in vivo setting at an early stage following tumor challenge, JC-hcea cells were grown on a small disk and implanted onto muscle as described (14). **Figures 3A and 3C** show histologically that JC-hcea cells proliferated from a monolayer to a tumor nodule after 5 days of in vivo growth in a naïve animal. In contrast to the naïve control, the implanted JC-hcea cells were nearly eradicated after 5 days of in vivo growth in animals immunized by topical application of AdCMV-hcea (**Figures 3B and 3D**). Moreover, a large number of immune effectors infiltrated into the implantation bed concomitantly with the eradication of breast tumor cells (**Figures 3B and 3D**). Histologic evidence thus supports the hypothesis that the death of tumor cells was mediated by a potent antitumor cellular immune response.

4. Relocation and degradation of foreign DNA after localized gene delivery in a noninvasive mode. In an attempt to determine whether topical application of an adenovirus vector could deliver foreign DNA beyond the inoculation area, we extracted DNA from various tissues, followed by amplification of the transgene as well as the adenovirus type 5 fiber gene by PCR after noninvasive delivery of AdCMV-luc (15) into neck skin. As shown in **Figure 4**, the full-length luciferase and fiber genes could be amplified from neck skin 3 hours post-inoculation. The full-length gene was usually undetectable in neck skin DNA after 1 day or in DNA extracted from other tissues. However, subfragments of both luciferase and fiber genes could be amplified from liver, whole blood, ear, abdominal skin, or lymph nodes using different sets of primers. No foreign DNA was detectable in any of the tissues 4 weeks post-inoculation. Results suggested that topical application of an adenovirus vector could deliver foreign DNA into a localized area in skin, although foreign DNA may be rapidly acquired by other cell types, degraded, and relocated into deep tissues. The elimination of foreign DNA in 4 weeks highlighted the safety of NIVS.

Task 5. Compare gene painting with other modes of genetic immunization.

We have compared gene painting with intramuscular injection of DNA-based vaccines. As shown in **Figures 1 and 2**, topical application of 10^8 pfu AdCMV-hcea was more potent in eliciting an anti-CEA antibody response as well as a protective immune response against tumor challenge than intramuscular injection of 100 μ g (equivalent to 10^{13} copies) pGT-37 DNA. We envision that only a small number of AdCMV-hcea particles could be absorbed by skin following topical application of 10^8 pfu. Results provide solid evidence that the outer layer of skin is more immunocompetent than muscle, and the surface of skin is an effective target site for vaccine administration.

KEY RESEARCH ACCOMPLISHMENTS

- Topical application of an adenovirus vector is capable of protecting animals against a lethal dose of tumor challenge. Although several different laboratories have shown that a humoral immune response could be elicited by topical application of adenovirus vectors (13, 16), DNA:adenovirus complexes (12), DNA:liposome complexes (12), naked DNA (4), or cholera toxin protein (6), this is the first demonstration that topical application of vaccines without causing tissue damage is able to protect animals against cancers in a disease setting.
- The in vivo cytotoxicity assay (14) provided evidence that the eradication of breast tumor cells in vivo may have been mediated by a potent antitumor cellular immune response.
- We have demonstrated that the outer layer of skin is more immunocompetent than muscle (13). This observation makes biological sense because the outer layer of skin is in frequent contact with environmental pathogens, and should be the focus of immunosurveillance.
- Construction of a helper-free gutless adenovirus system is underway.
- We have demonstrated that the skin does not allow environmental DNA to persist. Subfragments of degraded vector DNA could traffic to a variety of tissues following topical application, presumably via antigen-presenting cells.

REPORTABLE OUTCOMES

- **Publications:**

Shi Z, Zeng M, Yang G, Siegel F, Cain LJ, Van Kampen KR, Elmets CA, and Tang DC. 2001. Protection against tetanus by needle-free inoculation of adenovirus-vectored nasal and epicutaneous vaccines. *J. Virol.* (in press).

Zeng M, Smith SK, Siegel F, Shi Z, Van Kampen KR, Elmets CA, and Tang DC. 2001. AdEasy system made easier by selecting the viral backbone plasmid preceding homologous recombination. *BioTechniques* 31: 260-262.

Shi Z, Curiel DT, and Tang DC. 1999. DNA-based non-invasive vaccination onto the skin, *Vaccine* 17: 2136-2141.

- **Oral Presentations:**

Skin-targeted noninvasive vaccination against mammary tumor cells. *Era of Hope Department of Defense Breast Cancer Research Program Meeting*. Atlanta, Georgia, June 11, 2000

Analysis of target cells following vector-based noninvasive vaccination onto the skin. *The Third Annual Meeting of The American Society of Gene Therapy*. Denver, Colorado, June 3, 2000

Skin-targeted noninvasive vaccination. *National Vaccine Advisory Committee*. Washington, D.C., May 22, 2000

Skin-targeted non-invasive vaccine patches. *2000 Annual Meeting of the Society for Investigative Dermatology*. Chicago, Illinois, May 13, 2000

Skin-targeted noninvasive influenza vaccines. *Second Annual Meeting of the American Society of Gene Therapy*. Washington, DC, June 10, 1999

- **Patent:** Allowance of the U.S. patent "Vaccination by topical application of genetic vectors" (U.S. Serial No. 09/402,527)

- **Special Award:** Year 2000 Wallace H. Coulter Award for Innovation and Entrepreneurship with a stipend of \$100,000

- **Grant Awards:**

Principal Investigator, 2001-2002, *National Institutes of Health Small Business Innovation Research Program Phase I grant (#1-R43-AI-46198-01A1)*: "Noninvasive delivery of skin-targeted rabies vaccines", \$100,000

Principal Investigator, 2001-2002, *National Institutes of Health Small Business Innovation Research Program Phase I grant (#1-R43-AI-47558-01A2)*: "Noninvasive delivery of skin-targeted anthrax vaccines", \$100,000

Principal Investigator, 2001-2004, *Office of Naval Research Grant (#N00014-01-1-0945)*: "Vaccination by topical application of recombinant vectored vaccines", \$3,049,000

Principal Investigator, 2001-2002, *National Institutes of Health Small Business Technology Transfer Program Phase II grant (#2-R42-AI/HD-44520-02)*: "Non-invasive delivery of skin-targeted tetanus vaccines", \$282,625 (Renewable for 2002-2003)

Co-Principal Investigator, 2001-2006, *National Institutes of Health R01 grant (#1-R01-NS-43947-01)*: "Alzheimer vaccinations: Noninvasive vaccination by DNA-based vectors", \$1,250,000

Collaborator, 2001, *Department of Defense Small Business Innovation Research Program Phase I grant (#N00014-01-M-0178)*: "Needleless topical administration of dengue DNA vaccine", \$69,000

Preceptor, 2000-2001, *Dermatology Foundation Postdoctoral Fellowship*: "Development of a skin-targeted vaccine patch against anthrax", \$25,000

- **List of Personnel**
De-chu C. Tang, PhD
Zhongkai Shi, MD
Mingtao Zeng, PhD

CONCLUSIONS

We have demonstrated that noninvasive application of an adenovirus vector encoding a tumor-associated antigen onto the skin could elicit an immune response against the antigen, and protect vaccinees against tumor challenges. Evidence suggested that the efficacy of a "vaccine patch" may be even greater than that achievable by the commonly used intramuscular route, possibly due to the immunocompetence of the outer layer of skin. We envision that a noninvasive vaccine patch may emerge as a novel vaccination modality in the foreseeable future because the procedure is simple, effective, economical, painless, and safe. It may also boost vaccine coverage due to patient comfort.

REFERENCES

1. **Chen, H. H., L. M. Mack, R. Kelly, M. Ontell, S. Kochanek, and P. R. Clemens.** 1997. Persistence in muscle of an adenoviral vector that lacks all viral genes. *Proc. Natl. Acad. Sci. USA* **94**:1645-1650.
2. **Conry, R. M., A. F. LoBuglio, J. Kantor, J. Schlom, F. Loechel, S. E. Moore, L. A. Sumerel, D. L. Barlow, S. Abrams, and D. T. Curiel.** 1994. Immune response to a carcinoembryonic antigen polynucleotide vaccine. *Cancer Res.* **54**:1164-1168.
3. **Eisenbraun, M. D., D. H. Fuller, and J. R. Haynes.** 1993. Examination of parameters affecting the elicitation of humoral immune responses by particle bombardment-mediated genetic immunization. *DNA Cell Biol.* **12**:791-797.
4. **Fan, H., Q. Lin, G. R. Morrissey, and P. A. Khavari.** 1999. Immunization via hair follicles by topical application of naked DNA to normal skin. *Nat. Biotechnol.* **17**:870-872.
5. **Fynan, E. F., R. G. Webster, D. H. Fuller, J. R. Haynes, J. C. Santoro, and H. L. Robinson.** 1993. DNA vaccines: Protective immunizations by parenteral, mucosal, and gene-gun inoculations. *Proc. Natl. Acad. Sci. USA* **90**:11478-11482.
6. **Glenn, G. M., M. Rao, G. R. Matyas, and C. R. Alving.** 1998. Skin immunization made possible by cholera toxin. *Nature* **391**:851.
7. **Grable, M., and P. Hearing.** 1992. cis and trans requirements for the selective packaging of adenovirus type 5 DNA. *J. Virol.* **66**:723-731.
8. **Gunning, P., J. Leavitt, G. Muscat, S.-Y. Ng, and L. Kedes.** 1987. A human beta-actin expression vector system directs high-level accumulation of antisense transcripts. *Proc. Natl. Acad. Sci. USA* **84**:4831-4835.
9. **Hay, R. T., N. D. Stow, and I. M. McDougall.** 1984. Replication of adenovirus mini-chromosomes. *J. Mol. Biol.* **175**:493-510.
10. **He, T. C., S. Zhou, L. T. da Costa, J. Yu, K. W. Kinzler, and B. Vogelstein.** 1998. A simplified system for generating recombinant adenoviruses. *Proc. Natl. Acad. Sci. USA* **95**:2509-2514.
11. **Parks, R. J., L. Chen, M. Anton, U. Sankar, M. A. Rudnicki, and F. L. Graham.** 1996. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. *Proc. Nat. Acad. Sci. USA* **93**:13565-13570.
12. **Shi, Z., D. T. Curiel, and D. C. Tang.** 1999. DNA-based non-invasive vaccination onto the skin. *Vaccine* **17**:2136-2141.
13. **Shi, Z., M. Zeng, G. Yang, F. Siegel, L. J. Cain, K. R. Van Kampen, C. A. Elmets, and D. C. Tang.** 2001. Protection against tetanus by needle-free inoculation of adenovirus-vectored nasal and epicutaneous vaccines. *J. Virol.* (in press).
14. **Tang, D. C., A. F. Gazdar, and D. P. Carbone.** 1996. In vivo cytotoxicity assay for assessing immunity. *J. Immunol. Meth.* **189**:173-182.
15. **Tang, D. C., R. S. Jennelle, Z. Shi, R. I. Garver, Jr., D. P. Carbone, F. Loya, C.-H. Chang, and D. T. Curiel.** 1997. Overexpression of adenovirus-encoded

- transgenes from the cytomegalovirus immediate early promoter in irradiated tumor cells. Hum. Gene Ther. **8**:2117-2124.
16. **Tang, D. C., Z. Shi, and D. T. Curiel.** 1997. Vaccination onto bare skin. Nature **388**:729-730.

APPENDICES




Figure 1. ELISA antibodies generated by the AdCMV-hcea vector in mice. BALB/c mice (3 months old) were immunized by intramuscular (IM) injection of 100 μ g of pGT37 DNA, intranasal inoculation (IN) with a dose of 2.5×10^7 pfu (plaque-forming units) of AdCMV-hcea, or topical application using a patch by incubating 10^8 pfu of AdCMV-hcea with pre-shaved abdominal skin in a noninvasive mode. For patch-based immunization, the vector was spread as a thin film over naked skin with a piece of the Tegaderm patch (3M). Unabsorbed vectors were washed away in an hour. Each animal was immunized by the specified vector and route for 3 times every 3 weeks. Serum samples were assayed for anti-CEA antibodies 1 week after the last boost. Titers of anti-CEA IgG were determined by ELISA as described (12) using purified CEA (CalBiochem) as the capture antigen. Serum samples and peroxidase-conjugated goat anti-mouse IgG (Promega) were incubated sequentially on the plates for 1 hour at room temperature with extensive washing between each incubation. The end-point was calculated as the dilution of serum producing the same OD₄₉₀ as a 1/100 dilution of preimmune serum. Sera negative at the lowest dilution tested were assigned endpoint titers of 100. IM/pGT37, mice immunized by intramuscular injection of pGT37 DNA; IN/Ad-hcea, mice immunized by intranasal inoculation of AdCMV-hcea; NIVS/Ad-hcea, mice immunized by topical application of AdCMV-hcea; Naïve, non-immunized mice as a control group; NIVS/Ad-ha, mice immunized by topical application of an irrelevant vector AdCMV-PR8.ha (an adenovirus vector encoding an influenza hemagglutinin) as a control group. The data was plotted as geometric mean endpoint ELISA titers, where $n=9$ for

IM/pGT37, $n=19$ for IN/Ad-hcea, $n=9$ for NIVS/Ad-hcea, $n=10$ for naïve, and $n=10$ for NIVS/Ad-ha.




Figure 2. Protection from death after tumor challenge. BALB/c mice (3 months old) were immunized by a variety of vaccination modalities as described in **Figure 1** legend. One week after the last boost, mice were challenged subcutaneously with a lethal dose (3×10^5) of JC-hcea cells and monitored daily for survival. The data was plotted as % survival versus weeks after challenge. Naive, mice received no vaccines; NIVS/Ad-ha, mice immunized by topical application of AdCMV-PR8.ha; NIVS/Ad-hcea, mice immunized by topical application of AdCMV-hcea; IN/Ad-hcea, mice immunized by intranasal inoculation of AdCMV-hcea; IM/pGT37, mice immunized by intramuscular injection of pGT37 DNA. Numbers in parentheses represented the number of animals for each treatment.




Figure 3A



Figure 3B




Figure 3C





Figure 3D

Figure 3. Analysis of antitumor immune responses by in vivo cytotoxicity assay. BALB/c mice (3 months old) were immunized by topical application of AdCMV-hcea as described in **Figure 1** legend. One week after the last boost, 5×10^5 JC-hcea cells were implanted onto muscle as a monolayer using a small disk as described (14). After 5 days of in vivo growth, the implantation bed was cross sectioned, stained with hematoxylin and eosin, and examined under a light microscope. **A:** tissue section from the site of implantation of JC-hcea cells in a naïve mouse 5 days after implantation. Note the presence of a tumor layer on top of muscle (X33). **B:** tissue section from the site of implantation of JC-hcea cells in an AdCMV-hcea-based-vaccine-patch immunized mouse 5 days after implantation. Note the eradication of tumor cells and the infiltration of immune effectors into the implantation bed (X33). **C:** tissue section as shown in A was visualized at a higher magnification. Note the dominance of JC-hcea cells in the target cell layer with little immune intervention (X132). **D:** tissue section as shown in B was visualized at a higher magnification. Note the eradication of tumor cells and evidence for a potent immune intervention (X132).



M 1 2 3 4 5 6 7 8 9 10 11 12

Figure 4. Amplification of foreign DNA in various tissues after localized gene delivery in a noninvasive mode. AdCMV-luc was inoculated onto neck skin in a noninvasive mode as described (12). DNA was extracted by DNAZOL (GIBCOBRL), and amplified by the following sets of primers:

Luc5.1: GCGCCATTCTATCCTCTAGA
Luc3.1: ACAATTTGGACTTTCCGCC

Luc5.2: GTACCAGAGTCCTTTGATCG
Luc3.2: CCCTCGGGTGTAATCAGAAT

Fb5.1: CCGTCTGAAGATACCTTCAA
Fb3.1: ACCAGTCCCATGAAAATGAC

Fb5.2: GGCTCCTTTGCATGTAACAG
Fb3.2: CCTACTGTAATGGCACCTGT

Luc5.1 and Luc3.1 amplifies the 1.7 Kb full-length luciferase gene; Luc5.2 and Luc3.2 amplifies an 0.52 kb subfragment encompassing the central portion of the luciferase gene; Fb5.1 and Fb3.1 amplifies the 1.7 kb full-length adenovirus type 5 fiber gene; Fb5.2 and Fb3.2 amplifies an 0.55 kb subfragment encompassing the central portion of the fiber gene. Lane M, Molecular weight marker (Lambda DNA cleaved with HindIII); lane 1, full-length luciferase gene amplified by Luc5.1 and Luc3.1 from neck skin DNA 3 hours after NIVS; lane 2, a subfragment of luciferase DNA amplified by Luc5.2 and Luc3.2 from neck skin DNA 3 hours after NIVS; lane 3, a subfragment of luciferase DNA amplified by Luc5.2 and Luc3.2 from neck skin DNA 20 hours after NIVS; lane 4, a

subfragment of luciferase DNA amplified by Luc5.2 and Luc3.2 from mouse ear DNA 20 hours after NIVS; lane 5, a subfragment of luciferase DNA amplified by Luc5.2 and Luc3.2 from abdominal skin DNA 20 hours after NIVS; lane 6, a subfragment of luciferase DNA amplified by Luc5.2 and Luc3.2 from liver DNA 20 hours after NIVS; lane 7, a subfragment of luciferase DNA amplified by Luc5.2 and Luc3.2 from DNA extracted from whole blood 20 hours after NIVS; lane 8, a subfragment of luciferase DNA amplified by Luc5.2 and Luc3.2 from lymph node DNA 7 days after NIVS; lane 9, full-length fiber gene amplified by Fb5.1 and Fb3.1 from neck skin DNA 3 hours after NIVS; lane 10, a subfragment of fiber DNA amplified by Fb5.2 and Fb3.2 from neck skin DNA 3 hours after NIVS; lane 11, a subfragment of fiber DNA amplified by Fb5.2 and Fb3.2 from neck skin DNA 20 hours after NIVS; lane 12, a subfragment of fiber DNA amplified by Fb5.2 and Fb3.2 from mouse ear DNA 20 hours after NIVS. DNA from lymph nodes was extracted by pooling superficial cervical lymph nodes and axillary lymph nodes in DNAzol solution. DNA was amplified for 35 cycles at optimized annealing temperatures in a Stratagene Robocycler gradient 40 thermal cycler. Amplified DNA fragments were fractionated in 1% agarose gel and stained with ethidium bromide.

Protection against Tetanus by Needle-Free Inoculation of Adenovirus-Vectored Nasal and Epicutaneous Vaccines

ZHONGKAI SHI,¹ MINGTAO ZENG,² GUANG YANG,¹ FELIX SIEGEL,¹ LAURA J. CAIN,¹
 KENT R. VAN KAMPEN,¹ CRAIG A. ELMETS,² AND DE-CHU C. TANG^{1,2,3*}

¹*Vaxin, Inc., and* ²*Department of Dermatology and Gene Therapy Center,*
³*University of Alabama at Birmingham, Birmingham, Alabama*

Received 30 April 2001/Accepted 30 August 2001

The effectiveness of vaccination programs would be enhanced greatly through the availability of vaccines that can be administered simply and, preferably, painlessly without the need for timed booster injections. Tetanus is a prime example of a disease that is readily preventable by vaccination but remains a major threat to public health due to the problems associated with administration of the present vaccine. Here we show that a protective immune response against live *Clostridium tetani* infection in mice can be elicited by an adenovirus vector encoding the tetanus toxin C fragment when administered as a nasal or epicutaneous vaccine. The results suggest that these vaccination modalities would be effective needle-free alternatives. This is the first demonstration that absorption of a small number of vectored vaccines into the skin following topical application of a patch can provide protection against live bacteria in a disease setting.

Fn*

Tetanus continues to be a threat to public health with more than half a million fatalities each year being associated with infection with *Clostridium tetani* (23). Due to the ubiquitous distribution of the causal agent, vaccination is the most effective medical intervention for protection of the public against this deadly disease. The effectiveness of the vaccine is due, at least in part, to the fact that the sequences of the neurotoxin molecules are conserved among different strains of *C. tetani*, which permits elicitation of a protective immune response against all *C. tetani* strains through the use of a single vaccine (23). The effectiveness of the vaccine is limited, however, by the needle-based delivery method currently in use. Effective protection requires injection of three consecutive doses of the tetanus toxoid vaccine (16). Moreover, booster injections must be administered periodically during adulthood to compensate for the age-related decline in antitoxin levels (16). In developing countries, vaccine coverage against this disease is generally low due to failure to follow up as well as a lack of the trained medical personnel and facilities required for administration of the vaccine. In developed countries, although vaccine coverage in childhood is high, there is a general lack of compliance of adults with recommended schedules for booster injections (16). These factors have led to the realization that tetanus vaccination programs would be improved significantly worldwide through the development of low-cost, needle-free vaccines.

Needle-free vaccination requires the development of novel vaccines that can be administered safely and effectively. Several routes of administration are being considered. Both nasal and oral immunizations have been shown to be effective in eliciting an immune response against a number of pathogens. An alternative new modality is noninvasive vaccination onto

the skin (NIVS) by topical application of epicutaneous vaccines (8, 10, 11, 17, 18, 22), which would offer a greater safety margin and eliminate the discomfort associated with injections. Prior to our studies, it had not been demonstrated that topical application of epicutaneous vaccines could protect recipients against live pathogenic bacteria in a disease setting. This study was undertaken to determine if administration of a vaccine consisting of an adenovirus (Ad) recombinant (AdCMV-tetC) encoding the immunogenic but atoxic tetanus toxin C fragment (TetC) (16), when inoculated either intranasally or by an epicutaneous patch, can protect animals against a lethal challenge of live *C. tetani*. We report that administration of a single dose of this vaccine intranasally was 100% protective against intramuscular injection of a lethal amount of *C. tetani* cells and that administration of a single dose topically was protective in 80% of the mice with the protection rising to 100% when two booster applications were administered consecutively using a patch.

AQ: A

MATERIALS AND METHODS

Construction of expression vectors. The TetC fragment was amplified by PCR from plasmid pTET-nir (2) (provided by J. VanCott and J. McGhee, University of Alabama at Birmingham, Birmingham) using the primers 5tetC (5'-CGCGG ATCCACCATGGGAAAATCTGGATTGTTGGGTTG3') and 3tetC (5'-CGCG GATCCATCATTTGTCCATCCTTCATC3'). These DNA primers created unique *Bam*HI sites at the ends of the 1.35-kb TetC fragment with a synthetic eukaryotic ribosomal binding site (13) inserted in frame. The PCR-amplified fragment was subsequently cloned into the *Bam*HI site of the pACCMV.PLPA shuttle plasmid (12) under the transcriptional control of the human cytomegalovirus (CMV) early promoter to create the plasmid pAC-tetC. A replication-incompetent E1/E3-defective human Ad serotype 5-derived vector encoding TetC was constructed by homologous recombination between cotransfected pAC-tetC and pJM17 in human 293 cells as described (12). High-titer Ad stocks were prepared by ultracentrifugation over a cesium chloride gradient as described (20). A plasmid expression vector encoding TetC (pCMV-tetC) was constructed by cloning the same TetC fragment into the *Bam*HI site of the plasmid pVRI012 (provided by Vical, Inc., San Diego, Calif.) in the correct orientation under transcriptional control of the human CMV early promoter. The AdCMV-PR8.ha vector encoding the influenza A/PR/8/34 hemagglutinin (HA) was constructed as a control by excising the 1.8-kb *Bam*HI fragment containing the entire coding sequence of HA from the plasmid pDP122B (Amer-

* Corresponding author. Mailing address: Department of Dermatology, University of Alabama at Birmingham, VH-501, 1670 University Blvd., Birmingham, AL 35294-0019. Phone: (205) 975-5603. Fax: (205) 975-0455. E-mail: dctang@uab.edu.

ican Type Culture Collection [ATCC], Manassas, Va.), followed by cloning the HA gene into the *Bam*HI site of pACCMV.PLPA and subsequent homologous recombination with pJM17 in human 293 cells.

Immunization of mice. Young (2 to 3 months old) female BALB/c mice (Jackson Laboratory, Bar Harbor, Maine) were immunized by intranasal inoculation, topical application, intradermal injection, and intramuscular injection of vaccines (Ad-vectored or DNA-based).

NIVS was carried out by pipetting 10^7 to 10^{10} particles (the number of particles was determined by quantitative PCR as described below; 10^{10} particles were equivalent to approximately 10^8 PFU) of a recombinant Ad vector or 100 μ g of pCMV-tetC DNA as a thin film onto the pre-shaved abdominal skin of a mouse followed by coverage with a piece of the Tegaderm patch (3M). The skin was prepared by depilation with an electric trimmer in conjunction with gentle brushing using a soft-bristle brush without inducing erythema (Draize scores [15] of ≤ 1). Unabsorbed vectors were washed away after 1 h. The possibility of nasal or oral immunization through grooming was eliminated as described (18). Moreover, we have also demonstrated that the patch failed to immunize mice when vectors were removed from the skin a few seconds after topical application. The incompetence of a brief contact with respect to eliciting an immune response provides firm evidence that the immunization was mediated by skin transduction rather than inhalation of airborne vectors.

Intranasal inoculation was performed by pipetting 10^6 to 10^9 particles of a recombinant Ad vector, 10^9 particles of Ad5 (wild-type adenovirus serotype 5, ATCC number VR-5; ATCC), or 100 μ g of pCMV-tetC DNA into one of the nostrils of an anesthetized mouse. DNA-based vaccines (100 μ g of pCMV-tetC DNA) and AdCMV-tetC particles were inoculated by intramuscular injection into the hind-leg quadriceps as described (24). AdCMV-tetC particles were also injected intradermally into the abdominal skin of mice. Animals in some groups were given booster doses at weeks 3 and 6 after the primary immunization, whereas others were immunized only once. All experiments in mice were performed according to institutional guidelines.

Quantitative PCR. Two PCR primer sets were designed to selectively amplify subfragments of the Ad serotype 5 fiber gene. The primers Fb5.3 (5'-GCATTG ACTTGAAAGAGCCC3') and Fb3.3 (5'-AGGAACCATAGCCTGTGTTG) encompass a 560-bp fragment of the fiber gene, whereas the primers Fb5.4 (5'-GT AGCAGGAGGACTAAGGAT3') and Fb3.4 (5'-TATCCAAGTTGTGGGCTG AG3') encompass a 139-bp subfragment within the 560-bp fragment. The sensitivity of a nested PCR procedure was determined as follows. A PCR mix containing 1 μ g of genomic DNA extracted from the abdominal skin of a naive mouse was spiked with dilutions of purified AdCMV-tetC vector DNA ranging from 1 to 10,000 copies, followed by 40 cycles of amplification with the Fb5.3/Fb3.3 primer pair. After purifying the PCR products with the QIAquick PCR purification kit (Qiagen, Inc., Valencia, Calif.), DNA was subjected to another 40 cycles of amplification with the Fb5.4/Fb3.4 primer pair. Naive mouse skin DNA without the addition of Ad DNA templates was amplified with identical primer sets as a negative control. Following this amplification protocol, we consistently detected 10 or more copies 100% of the time in several independent experiments. It was therefore concluded that the sensitivity of the assay was 10 copies or less.

To quantitatively determine the number of vectors that were absorbed by the skin following topical application of an Ad-vectored vaccine, total DNA was extracted from the skin tissue underneath the patch at 1 and 24 h postimmunization. The skin was washed under tap water and blotted dry to remove any unbound vectors before resection. Purified DNA was diluted in 10-fold increments and subjected to amplification with the nested PCR protocol. The amount of DNA per PCR was kept constant by adding naive mouse skin DNA to a final quantity of 1 μ g. The highest dilution of a DNA sample that generated a detectable signal should contain the AdCMV-tetC vector in the range of 10 particles, under the assumption that each vector contains a single copy of the fiber gene. DNA was extracted using the DNAzol solution (Life Technologies, Rockville, Md.) and amplified at an optimized annealing temperature (54°C) in a thermal cycler. Amplified DNA fragments were fractionated on a 1.5% agarose gel and visualized as described (28). Samples were scored as positive if the diagnostic band was detected.

ELISA. Titers of anti-TetC immunoglobulin G (IgG) were determined by enzyme-linked immunosorbent assay (ELISA) as described (18) using purified TetC protein (CalBiochem, San Diego, Calif.) as the capture antigen. Briefly, serum samples and peroxidase-conjugated goat anti-mouse IgG (Promega Corp., Madison, Wis.) were incubated sequentially on the plates with extensive washing between incubations. The endpoint was calculated as the dilution of serum producing the same optical density at 490 nm as a 1/100 dilution of preimmune serum. Sera negative at the lowest dilution tested were assigned endpoint titers of 1.

Challenge by live *C. tetani*. Mice were challenged by footpad injection of 6×10^3 (50% lethal dose [LD₅₀], 12.5) or 6×10^4 (LD₅₀, 125) *C. tetani* cells in a volume of 50 μ l. Distortion of the backbone due to paralysis was taken as the disease end point. The LD₅₀ was defined as the number of *C. tetani* cells capable of distorting the backbone of 50% of the mice in a group of 10 animals within a week following footpad injection. A toxigenic strain of *C. tetani* (ATCC number 9441; ATCC) was cultivated in the ATCC 38 beef liver medium for anaerobes at 37°C under anaerobic gas mixture (80% N₂-10% CO₂-10% H₂). Gram-stained cells were counted under a light microscope using a hemacytometer. Animals either succumbed to the disease or were euthanatized when backbone distortion occurred.

Anti-Ad neutralizing antibody assay. Anti-Ad neutralizing antibodies were measured as cytopathic effect (CPE)-inhibiting antibodies by incubating diluted serum samples with 100 PFU of Ad at 4°C for 1 h, followed by adding the neutralized particles to 10^5 human 293 cells in a tissue culture well. CPEs were scored from triplicate samples daily by examining the monolayers under a light microscope. The assay was terminated when viruses mixed with a 1/10 dilution of preimmune serum produced 100% CPE (4 days postinfection in this experiment). Sera capable of completely inhibiting CPE (defined as the disruption of confluent monolayers) at the highest dilution tested were assigned endpoint CPE inhibition (CPEI) titers of 1. This assay tests the ability of specific antibodies to prevent Ad from infecting human 293 cells and measures a subset of neutralizing antibodies.

RESULTS

Elicitation of an anti-TetC humoral immune response. The AdCMV-tetC vector was used in these studies to permit administration of a vectored tetanus vaccine in a needle-free manner. The needle-free routes of administration included topical and intranasal inoculations. A DNA-based vaccine (pCMV-tetC) also was administered by these routes as well as by intramuscular injection as another control. We report here that the efficiency of vector absorption into the skin was very low, with approximately 1 in 4,000 particles being taken within 1 h of the topical application (Fig. 1A). Most of the vectors applied to the surface failed to bind to the skin and were subsequently washed away. No adverse effects associated with inoculation were observed in any of the immunized mice during the course of these studies. Absorption of AdCMV-tetC particles following topical application was more effective in eliciting an anti-TetC antibody response than intradermal or intramuscular injection of the same vector at equivalent doses, as determined by seroconversion, which was monitored by analysis of sera from tail bleeds for the production of IgG antibody directed against TetC using an ELISA (Fig. 1B).

Seroconversion was observed in all of the mice immunized intranasally with $\geq 10^6$ particles (groups B to E, M, and P to R) (Table 1) or topically with $\geq 10^9$ particles (groups I, J, N, and T to V) (Table 1) of the AdCMV-tetC vector. The anti-TetC geometric mean titer (GMT) increased as the dose of AdCMV-tetC escalated (groups B to E and G to I) (Table 1). The level of anti-TetC reached a plateau when $\geq 10^9$ particles of AdCMV-tetC were applied topically (groups I and J) (Table 1).

The TetC-specific IgG response of the mice that were administered AdCMV-tetC through application of an epicutaneous patch could be boosted to a high-titer response by three consecutive applications of the patch (GMT = 29,406 for group U compared to GMT = 5,971 for group T) (Table 1). The highest titers of antibody were observed in the mice administered AdCMV-tetC by the intranasal route (GMT $\geq$ 409,600; groups E, P, and Q) (Table 1). Intranasal boosting did not result in a significant increase in the anti-TetC titer (group




FIG. 1. Outer layer of skin as immunocompetent tissue with low capacity to absorb vectors from the environment. (A) Determination of the number (#) of vectors absorbed by the skin following topical application. One and 24 h after topical application of 10^{10} particles of the AdCMV-tetC vector using a patch, the mouse abdominal skin underneath the patch was washed, blotted dry, resected, and immediately homogenized in the DNAzol solution for DNA extraction. The number of skin-associated vectors per animal was determined quantitatively by amplifying subfragments of the adenoviral fiber gene with the nested PCR procedure in conjunction with limited dilutions, under the assumption that each vector contains a single fiber gene. Three individual animals were analyzed at each time point. The data shown are means $\pm$ standard deviations. (B) Comparison of different modes for vaccine administration. AdCMV-tetC particles of various doses were inoculated into mice by topical application and intradermal and intramuscular injection. Animals were immunized only once. Sera were harvested for ELISA-based anti-TetC analysis 3 and 6 weeks postimmunization. NIVS-1, mice immunized by topical application of 10^{10} Ad particles with approximately 10^6 particles absorbed by the skin, as determined by the method described in panel A; ID-1, mice immunized by intradermal injection of 10^6 Ad particles; ID-2, mice immunized by intradermal injection of 10^8 Ad particles; ID-3, mice immunized by intradermal injection of 10^{10} Ad particles; IM-1, mice immunized by intramuscular injection of 10^6 Ad particles; IM-2, mice immunized by intramuscular injection of 10^8 Ad particles; IM-3, mice immunized by intramuscular injection of 10^{10} Ad particles. The data shown are GMTs for anti-TetC antibodies (5 animals per group for ID-1 and IM-3; 10

P compared to group Q) (Table 1). Intramuscular injection of 100 μ g (equivalent to approximately 10^{13} copies) of pCMV-tetC DNA induced seroconversion in all animals; however, only a weak immune response was produced (GMT = 1,055; group W) (Table 1). Intranasal inoculation (group A) (Table 1) and topical application (group F) (Table 1) of pCMV-tetC DNA were ineffective in eliciting any detectable anti-TetC antibodies.

Protection against tetanus following live bacterial challenge. Seroconversion does not necessarily confer protection. Therefore, the protective effects of the vaccination regimens were determined by challenge with a toxigenic strain of *C. tetani* injected in the footpad at a dose of 6×10^3 cells (LD_{50} , 12.5). On such challenge, unprotected mice inevitably succumbed to tetanus with paralysis of the inoculated paw followed by distortion of the backbone and death. Administration of AdCMV-tetC as a nasal vaccine at a dose of $\geq 10^7$ particles conferred complete protection in all animals after a single inoculation or three consecutive inoculations ($P < 0.001$) (Table 1; Fig. 2A and 3A). Full protection was also achieved after three consecutive applications of 10^{10} particles of AdCMV-tetC as an epicutaneous vaccine ($P < 0.001$), with 80% of the mice being protected ($P < 0.001$) by a single application (Table 1; Fig. 2B and 3B). All naive animals that were not immunized (groups K and X), as well as mice immunized with an irrelevant Ad vector (i.e., AdCMV-PR8.ha in groups O and S), were paralyzed severely or succumbed to tetanus within 4 days (Table 1; Fig. 3). Some mice that survived the challenge have been kept alive for up to 4 months and no symptoms of tetanus developed in any of the animals after day 10. Analysis of the anti-TetC IgG levels in the mice indicated that 100% survival was correlated with an anti-TetC titer of $> 6,400$, although some animals with a lower titer could still survive the challenge.

Only 10% of the mice (group W) were protected by a single intramuscular injection of 100 μ g of pCMV-tetC DNA despite a low-level seroconversion that occurred in all animals (Table 1). This low potency is consistent with a report that intramuscular injection of DNA is not very effective in protecting mice against tetanus (16).

We have defined the limit of the protective capacity of current Ad-vectored vaccines. A single inoculation of epicutaneous vaccines by topical application of 10^{10} AdCMV-tetC particles conferred no protection when animals were challenged with 6×10^4 *C. tetani* cells (LD_{50} , 125; group N), whereas a single intranasal inoculation of 10^9 AdCMV-tetC particles protected only 20% of the immunized mice when challenged at this high dose (group M) (Table 1; Fig. 4). It is conceivable that larger animals with anti-TetC of the same titer may be able to counteract a higher number of invading bacteria because there are more neutralizing antibody molecules in the reservoir, and more toxin molecules may be required to paralyze a larger animal.

animals per group for NIVS-1, ID-2, ID-3, IM-1, and IM-2). No anti-TetC antibodies were detectable in some groups (both 3 and 6 weeks postimmunization in ID-1; 3 weeks postimmunization in IM-1), and low columns representing negative responses were included for visualization.

TABLE 1. Summary of immune responses in mice^a

AQ: B	Expt and group ^b	Vector (dose) ^c	Ad5 ^d	Route	No. of boosts	No. of mice producing anti-TetC/no. of mice in group	Anti-TetC IgG serum GMT (range) ^e	<i>C. tetani</i> challenge survival ^f	P
AQ: C	I								
	A	pCMV-tetC (100 µg)		i.n.	0	0/10	≤100	0 (0/10)	1
	B	AdCMV-tetC (10 ⁶ particles)		i.n.	0	10/10	4,222 (1,600–25,600)	50 (5/10)	0.016
	C	AdCMV-tetC (10 ⁷ particles)		i.n.	0	10/10	117,627 (25,600–409,600)	100 (10/10)	<0.001
	D	AdCMV-tetC (10 ⁸ particles)		i.n.	0	10/10	235,253 (25,600–409,600)	100 (10/10)	<0.001
	E	AdCMV-tetC (10 ⁹ particles)		i.n.	0	10/10	429,300 (163,800–1,638,400)	100 (10/10)	<0.001
	F	pCMV-tetC (100 µg)		NIVS	0	0/10	≤100	0 (0/10)	1
	G	AdCMV-tetC (10 ⁷ particles)		NIVS	0	0/10	≤100	0 (0/10)	1
	H	AdCMV-tetC (10 ⁸ particles)		NIVS	0	8/10	765 (100–25,600)	30 (3/10)	0.105
	I	AdCMV-tetC (10 ⁹ particles)		NIVS	0	10/10	16,890 (1,600–25,600)	80 (8/10)	<0.001
	J	AdCMV-tetC (10 ¹⁰ particles)		NIVS	0	10/10	16,890 (640–25,600)	80 (8/10)	<0.001
	K					0/10	≤100	0 (0/10)	1
	L					0/10	≤100	0 (0/10)	1
	M	AdCMV-tetC (10 ⁹ particles)		i.n.	0	10/10	470,507 (102,400–1,638,400)	20 (2/10)	0.474
	N	AdCMV-tetC (10 ¹⁰ particles)		NIVS	0	10/10	16,890 (6,400–25,600)	0 (0/10)	1
II	O	AdCMV-PR8.ha (10 ¹⁰ particles)		i.n.	2	0/10	≤100	0 (0/10)	1
	P	AdCMV-tetC (10 ⁹ particles)		i.n.	0	7/7	409,600 (409,600–409,600)	100 (7/7)	<0.001
	Q	AdCMV-tetC (10 ⁹ particles)		i.n.	2	10/10	409,600 (409,600–409,600)	100 (10/10)	<0.001
	R	AdCMV-tetC (10 ⁹ particles)	171	i.n.	2	10/10	382,170 (204,800–409,600)	100 (10/10)	<0.001
	S	AdCMV-PR8.ha (10 ¹⁰ particles)		NIVS	2	0/10	≤100	0 (0/10)	1
	T	AdCMV-tetC (10 ¹⁰ particles)		NIVS	0	10/10	5,971 (1,600–25,600)	80 (8/10)	<0.001
	U	AdCMV-tetC (10 ¹⁰ particles)		NIVS	2	10/10	29,406 (6,400–102,400)	100 (10/10)	<0.001
	V	AdCMV-tetC (10 ¹⁰ particles)	197	NIVS	2	9/9	1,866 (400–25,600)	67 (6/9)	0.003
	W	pCMV-tetC (100 µg)		i.m.	0	10/10	1,055 (400–102,400)	10 (1/10)	1
	X					0/10	≤100	0 (0/10)	1

^a Mice were immunized by intranasal (i.n.) inoculation, topical application (NIVS), or intramuscular (i.m.) injection of vaccines (Ad-vectored or DNA-based). To determine the optimal dose of vectored vaccines, escalating amounts of AdCMV-tetC were inoculated as nasal or epicutaneous vaccines. To determine a booster effect, animals were either immunized once or the primary immunization was followed by two subsequent boosts at intervals of 3 weeks. To analyze the impact of anti-Ad immunity to the efficacy of Ad-vectored vaccines, Ad5 was inoculated i.n. into animals prior to the primary immunization. Titers of anti-TetC IgG were determined by ELISA. Animals were challenged by footpad injection of live *C. tetani* cells. Paralysis and survival were scored until 14 (experiment I) or 120 (experiment II) days postchallenge. Mice were euthanized when backbone distortion occurred. P, statistical significance of the protection compared to the naïve control group by Fisher's exact test.

^b Mice in groups L to N were challenged with 6×10^4 *C. tetani* cells; mice in other groups were all challenged with 6×10^3 *C. tetani* cells.

^c Groups K, L, and X were naïve control mice; they did not receive vectored vaccines.

^d Ad5 (10⁹ particles) was inoculated intranasally 2 weeks prior to the primary immunization (groups R and V). Numbers represent the GMT of anti-Ad neutralization antibodies (CPEI titers ranged from 160 to 320 for both groups R and V) at the time of primary immunization.

^e Numbers represent anti-TetC IgG serum titers 5 (experiment I) or 7 (experiment II) weeks after the primary immunization.

^f The first number represents the percentage of survivors; the numbers in parentheses represent the number of animals surviving out of the number of animals in that group.

Protection in the context of preexisting immunity to Ad. The possibility that preexisting immunity to Ad could interfere with the ability of an Ad-vectored vaccine to elicit a protective immune response was considered. We investigated this possibility by inoculating the mice intranasally with Ad5 2 weeks prior to the primary administration of the vaccine. Anti-Ad neutralization antibodies were subsequently detected in all mice with exposure to Ad5 (CPEI GMT = 171 for group R and CPEI GMT = 197 for group V) (Table 1).

Even though the animals had preexisting immunity to Ad, administration of AdCMV-tetC either intranasally or through an epicutaneous patch induced an IgG response to TetC (GMT = 382,170 for group R; GMT = 1,866 for group V) (Table 1). Protection against *C. tetani* challenge was unaffected by preexisting immunity to Ad in the mice that were administered AdCMV-tetC intranasally (group R, $P < 0.001$) (Fig. 5A). Although preexisting immunity did affect the level of protection conferred by the vaccine administered through the epicutaneous patch (group V, $P = 0.003$) (Fig. 5B), protection was positively demonstrated. Therefore, the immune repertoire can be mobilized toward a protective response against live *C. tetani*-mediated pathogenesis either by intranasal inoc-

ulation or topical application of an Ad-vectored vaccine in animals that have preexisting immunity to Ad.

DISCUSSION

A new generation of vaccines is required if the effectiveness of the global vaccine programs is to be enhanced. This demonstration that intranasal inoculation or topical application of an Ad-vectored vaccine results in statistically and preclinically significant protection against tetanus in mice ushers in two new modalities for the needle-free administration of tetanus vaccines. The vaccine used in these studies was a recombinant Ad vector encoding the atoxic C fragment of the tetanus toxin. The use of Ad-vectored vaccines is an attractive strategy due to its efficacy in eliciting an immune response. Another positive aspect of this strategy is the possible negation of the current requirement for an unbroken cold chain, since lyophilized Ad vectors can be reconstituted into active infectious particles (5).

Although all naïve mice and those immunized with irrelevant control vectors were paralyzed within 4 days of challenge, the partially protected animals exhibited symptoms of tetanus at a later date. Death occurred in some partially protected




FIG. 2. Dose-response protection against tetanus after bacterial challenge. Animals were immunized by inoculation with Ad-vectored vaccines at escalating doses. Five weeks postimmunization, mice were challenged by footpad injection of a lethal dose (6×10^3) of live *C. tetani* cells and monitored daily for survival for 14 days. (A) Dose-response protection against tetanus by a single intranasal inoculation of the AdCMV-tetC vector at an escalating dose. Groups B to E, mice were immunized by intranasal inoculation of the AdCMV-tetC vector at an escalating dose (10^6 to 10^9 particles; the specific dose for each group is shown in Table 1); group A, mice were immunized by intranasal inoculation of 100 μ g of pCMV-tetC DNA. (B) Dose-response protection against tetanus by a single topical application of the AdCMV-tetC vector at an escalating dose. Groups G to J, mice were immunized by topical application of the AdCMV-tetC vector at an escalating dose (10^7 to 10^{10} particles; the specific dose for each group is shown in Table 1); group F, mice were immunized by topical application of 100 μ g of pCMV-tetC DNA. The data were plotted as percent survival versus number of days after challenge. Numbers in parentheses represent the number of animals for each treatment.

animals as late as 10 days postchallenge (Fig. 5B). This suggests that there is a critical initial time period during infection with *C. tetani* in which the host immune system is undergoing mobilization prior to achieving a response sufficient to eradicate the pathogen. Although the effectiveness of a tetanus vaccine may depend on its ability to rapidly induce adequate levels of antitoxin, it remains to be seen whether an anti-TetC cellular immune response (16) is involved in the eradication of live *C. tetani* cells in vivo.

Ad-vectored nasal vaccine elicited high titers of anti-TetC antibodies after a single administration, and these levels were not increased by short-term booster inoculations (groups P and

Q). Moreover, as reported previously for rabies (27), the high titers were not suppressed appreciably by preexposure to Ad (groups Q and R). The potency of the intranasal inoculation may reflect the natural tropism of the Ad vector for the airway, where it can transduce a large number of cells and possibly activate the mucosal immune machinery to its full potential.

Although administration of the Ad-vectored vaccine through an epicutaneous patch was capable of causing seroconversion and was effective in protecting the animals from challenge with live *C. tetani* particularly after boosting, the titers of anti-TetC antibodies were relatively low when compared to those elicited by intranasal inoculations. Several strategies for optimization




FIG. 3. Effects of booster applications in protecting mice against tetanus after bacterial challenge. Mice were immunized either once or three times at intervals of 3 weeks. Eight weeks after the primary immunization, mice were challenged by footpad injection of 6×10^3 *C. tetani* cells and monitored daily for survival for 14 days. (A) Mice were immunized by intranasal inoculation with Ad vectors. Group O, intranasal inoculation with AdCMV-PR8.ha three times; group P, intranasal inoculation with AdCMV-tetC once; group Q, intranasal inoculation with AdCMV-tetC three times. (B) Mice were immunized by topical application of Ad vectors. Group S, topical application of AdCMV-PR8.ha three times; group T, topical application of AdCMV-tetC once; group U, topical application of AdCMV-tetC three times; group X, naïve control mice. The data were plotted as described in the legend to Fig. 2. Numbers in parentheses represent the number of animals for each treatment.

of the response can be envisioned. As boosting was effective in these studies, the immune response could be enhanced by applying the vaccine patch multiple times or over a large area. The efficacy of epicutaneous administration also may be enhanced by increasing the affinity of the Ad vector for specific cell types within the outer layer of skin (e.g., terminally differentiated keratinocytes, antigen-presenting cells that traffic to the surface, or other cell types along the skin barrier), which may be achieved by inserting a preselected ligand into the adenoviral fiber as previously described (6, 25) in an attempt to augment transduction efficiency in a targeted manner. Such a "skin-binding" vector could be a more effective carrier for epicutaneous vaccines than the current Ad vector due to the overexpression of antigens in specific cell types that are potent immunostimulators.

Emerging evidence suggests that the outer layer of skin may be more immunocompetent than deep tissues (7, 9) (Fig. 1B). It is also conceivable that the immune system may focus its surveillance on an interface that is in frequent contact with environmental pathogens. Overexpression of immunogens from a small number of vectored vaccines in the outer layer of

skin may thus elicit a more potent immune response than the inoculation of an equivalent dose into deep tissues. This is borne out by the magnitude of the immune response that was elicited (Table 1 and Fig. 1B) by a relatively low number of vectors absorbed following topical application (Fig. 1A). However, it is unclear whether the leveling off of vaccine potency following topical application of AdCMV-tetC at a dose of $\geq 10^9$ particles (groups G to J) (Table 1) was due to saturation of the antigen expression machinery or the antigen presenting capacity within a restricted subset of skin. A skin-targeted vector may amplify antigen expression in the outer layer of skin; however, strategies to mobilize antigen-presenting cells will have to be exploited if antigen presentation should appear to be the limiting step.

The suppression of the efficacy of the Ad-vectored epicutaneous vaccine by preexisting immunity to Ad (Table 1 and Fig. 5) is a problem that must be circumvented during the development of an Ad-vectored vaccine patch. It is likely that the suppression may not be attributed to anti-Ad antibodies that prevent Ad vectors from entering target cells, because a reporter gene (i.e., luciferase) can be effectively expressed in skin




FIG. 4. Protective capacity of Ad-vectored vaccines. Five weeks postimmunization, mice were challenged by footpad injection of either 6×10^3 or 6×10^4 *C. tetani* cells and monitored daily for survival for 14 days. Groups E and M, mice immunized by a single intranasal inoculation with AdCMV-tetC vectors were challenged with 6×10^3 and 6×10^4 *C. tetani* cells, respectively; groups J and N, mice immunized by a single topical application of AdCMV-tetC vectors were challenged with 6×10^3 and 6×10^4 *C. tetani* cells, respectively; group L, naïve mice were challenged with 6×10^4 *C. tetani* cells. The data were plotted as described in the legend to Fig. 2. Numbers in parentheses represent the number of animals for each treatment.

from an Ad vector following topical application in mice with preexposure to Ad (data not shown). It is also conceivable that anti-Ad antibodies may not be able to reach the surface of skin in sufficient quantities to neutralize concentrated vectors. A skin-targeted vector may lessen the impact of preexisting immunity to Ad by overexpressing antigens. Alternatively, the capacity for a gutless Ad (3) to mediate long-term transgene expression in immunocompetent animals also may allow an epicutaneous vaccine to elicit a potent immune response in the presence of preexisting anti-Ad immunity if immunosuppression is attributed to rapid elimination of transduced cells by an anti-Ad cellular immune response.

The rapid loss of vector DNA observed in these studies after

topical application (Fig. 1A) may be beneficial in preventing the persistence of exogenous DNA. Presumably, the mechanisms that have evolved to degrade or expel skin-associated environmental DNA in order to protect the genomic integrity of the host may contribute to the elimination of the vector DNA following topical application. In contrast to the short half-life of vectored epicutaneous vaccines, DNA-based vaccines have been reported to persist in animals for up to a year after intramuscular injections (26). Conceivably, the degradation of vectored epicutaneous vaccines may contribute to not only a safer vaccine but also a more effective one, as the transient expression of antigens in vivo could foster the longevity of memory T cells by minimizing antigen-induced apoptosis of T lymphocytes (19, 29). If efficacy should be limited by overdegradation, the problem potentially can be circumvented by booster applications as shown in this report (Table 1 and Fig. 3B).

It has been demonstrated previously that topical application of TetC protein in conjunction with cholera toxin is capable of eliciting anti-TetC antibodies in mice (10). It is unclear, however, whether a protein-based epicutaneous vaccine is able to protect animals against bacterial infections. The profile of the immune response elicited by vectored vaccines may be quite different from that induced by their protein-based counterparts since the vector DNA dictates the synthesis of exogenous proteins in animals' own cells after inoculation, and antigens produced in situ can often induce a more solid immunity than inoculation of protein-based vaccines (14). Evidence suggests that an Ad vector encoding TetC could be more effective than the TetC protein as an epicutaneous vaccine since the latter required the coadministration of cholera toxin as an adjuvant (10), whereas topical application of the AdCMV-tetC vector alone was able to protect all of the recipients against challenge with live *C. tetani* (Fig. 3B). Although topical application of plasmid DNA also has been shown capable of eliciting an antibody response (1, 8, 18), it has not been demonstrated that this modality can evoke any protective immunity. Topical application of naked plasmid DNA, in the absence of an association with Ad or liposome, produced no detectable gene expression in the skin (4, 18), and we report here that naked plasmid DNA was ineffective in eliciting an anti-TetC antibody response or a protective immune response against tetanus following either topical or intranasal inoculations (Table 1 and Fig. 2). The potency of an Ad-vectored vaccine may be attributed to an efficient gene delivery in conjunction with robust transgene expression when compared to its plasmid counterpart (21).

In these studies, intranasal inoculation was more effective than topical application with respect to eliciting an immune response, although this difference may be attributed, in part, to the low absorption efficiency of the skin (Fig. 1A). There are, however, some issues that detract from the practicality of intranasal administration of vaccines. A major concern is the possibility of the elicitation of a severe adverse pulmonary reaction in those individuals who are allergic to components of the vaccine or in individuals with underlying pulmonary disease. Moreover, intranasal administration can irritate the nose, causing responses that result in expulsion of an unpredictable amount of the vaccine.

The recent report that a humoral immune response could be




FIG. 5. Protection in the context of preexisting immunity to Ad. Two groups of mice were inoculated intranasally with 10^9 particles of Ad5 2 weeks prior to the primary immunization. Eight weeks after immunization with the AdCMV-tetC vector, animals were challenged by footpad injection of 6×10^5 *C. tetani* cells and monitored daily for survival for 14 days. (A) Protection by intranasal inoculation. Groups R and Q, mice immunized by intranasal inoculation with the AdCMV-tetC vector with and without preexposure to Ad5, respectively. (B) Protection by topical application of a patch. Groups V and U, mice immunized by topical application of the AdCMV-tetC vector with and without preexposure to Ad5, respectively. Groups O, S, and X are control groups described in the legend to Fig. 3. The data were plotted as described in the legend to Fig. 2. Numbers in parentheses represent the number of animals for each treatment.

elicited in humans by topical application of a vaccine patch (11) suggests that the outer layer of human skin may be as immunocompetent as that of their animal counterparts. Although an experimental murine tumor could be arrested following topical application of tumor epitope peptides (17), it has not been demonstrated, prior to our studies, that a pathogen of human relevance could be arrested following topical application of any vaccines. We have shown, for the first time, that topical application of a vectored vaccine patch in a non-invasive manner could protect animals against infection by live bacteria in a disease setting.

By expressing antigens in an immunocompetent area without causing tissue damage, nasal and epicutaneous vaccines may emerge as preferred modalities for the inoculation of future vaccines in a simple, effective, economical, painless, and safe manner.

ACKNOWLEDGMENTS

We thank M. Alder and D. Curiel for their support, F. Hunter and D. Grove for editorial assistance, L. Timares for critical reading of the manuscript, P. Bucy for consultation, J. VanCott and J. McGhee for providing the plasmid pTET-nir, R. Gerard for providing the plasmid

pACCMV.PLPA, F. Graham for providing the plasmid pJM17, and Vical, Inc., for providing the plasmid pVR-1012. We also thank M. Kinzlaw, S. Smith, and S. Lorengel for technical assistance.

This work was supported by National Institutes of Health grants 2-R42-AI44520-02, 1-R41-AI44520-01, and 1-R43-AI43802-01; Office of Naval Research Grant N00014-01-1-0945; U.S. Army grant DAMD-17-98-1-8173; and investments from the Emerging Technology Partners and the Paradigm Venture Partners I, LLC. D.C.T. was also supported by the Year 2000 Wallace H. Coulter Award for Innovation and Entrepreneurship, and M.Z. was supported by a postdoctoral fellowship from the Dermatology Foundation and Mary Kay Holding Corporation.

REFERENCES

1. Carson, D. A., and E. Raz. October 1997. Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides. U.S. patent 5,679,647.
2. Chatfield, S. N., I. G. Charles, A. J. Makoff, M. D. Oxeer, G. Dougan, D. Pickard, D. Slater, and N. F. Fairweather. 1992. Use of the nirB promoter to direct the stable expression of heterologous antigens in *Salmonella* oral vaccine strains: development of a single-dose oral tetanus vaccine. *Bio/Technology* 10:888-892.
3. Chen, H. H., L. M. Mack, R. Kelly, M. Ontell, S. Kochanek, and P. R. Clemens. 1997. Persistence in muscle of an adenoviral vector that lacks all viral genes. *Proc. Natl. Acad. Sci. USA* 94:1645-1650.
4. Ciernik, I. F., B. H. Krayenbuhl, and D. P. Carbone. 1996. Puncture-mediated gene transfer to the skin. *Hum. Gene Ther.* 7:893-899.

rich4/jv-jvi/jv-jvi/jv2301/jv0833d01a	lahendrij	S=6	9/27/01	13:12	Art:	Input-1st disk, 2nd
---------------------------------------	-----------	-----	---------	-------	------	---------------------

VOL. 75, 2001

ADENOVIRUS AS A CARRIER FOR NEEDLE-FREE VACCINATION 9

5. Croyle, M. A., D. J. Anderson, B. J. Roessler, and G. L. Amidon. 1998. Development of a highly efficient purification process for recombinant adenoviral vectors for oral gene delivery. *Pharm. Dev. Technol.* 3:365-372.
6. Dmitriev, I., V. Krasnykh, C. R. Miller, M. Wang, E. Kashentseva, G. Mikheeva, N. Belousova, and D. T. Curiel. 1998. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. *J. Virol.* 72:9706-9713.
7. Eisenbraun, M. D., D. H. Fuller, and J. R. Haynes. 1993. Examination of parameters affecting the elicitation of humoral immune responses by particle bombardment-mediated genetic immunization. *DNA Cell Biol.* 12:791-797.
8. Fan, H., Q. Lin, G. R. Morrissey, and P. A. Khavari. 1999. Immunization via hair follicles by topical application of naked DNA to normal skin. *Nat. Biotechnol.* 17:870-872.
9. Fynan, E. F., R. G. Webster, D. H. Fuller, J. R. Haynes, J. C. Santoro, and H. L. Robinson. 1993. DNA vaccines: protective immunizations by parental, mucosal, and gene-gun inoculations. *Proc. Natl. Acad. Sci. USA* 90: 11478-11482.
10. Glenn, G. M., T. Scharton-Kersten, R. Vassell, G. R. Matyas, and C. R. Alving. 1999. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants. *Infect. Immun.* 67:1100-1106.
11. Glenn, G. M., D. N. Taylor, X. Li, S. Frankel, A. Montemmarano, and C. R. Alving. 2000. Transcutaneous immunization: a human vaccine delivery strategy using a patch. *Nat. Med.* 6:1403-1406.
12. Gomez-Foix, A. M., W. S. Coats, S. Baque, T. Alam, R. D. Gerard, and C. B. Newgard. 1992. Adenovirus-mediated transfer of the muscle glycogen phosphorylase gene into hepatocytes confers altered regulation of glycogen metabolism. *J. Biol. Chem.* 267:25129-25134.
13. Kozak, M. 1986. Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes. *Cell* 44:283-292.
14. McDonnell, W. M., and F. K. Askari. 1996. DNA vaccines. *N. Engl. J. Med.* 334:42-45.
15. Parker, S. E., F. Borellini, M. L. Wenk, P. Hobart, S. L. Hoffman, R. Hedstrom, T. Le, and J. A. Norman. 1999. Plasmid DNA malaria vaccine: tissue distribution and safety studies in mice and rabbits. *Hum. Gene Ther.* 10:741-758.
16. Saikh, K. U., J. Sesno, P. Brandler, and R. G. Ulrich. 1998. Are DNA-based vaccines useful for protection against secreted bacterial toxins? Tetanus toxin test case. *Vaccine* 16:1029-1038.
17. Seo, N., Y. Tokura, T. Nishijima, H. Hashizume, F. Furukawa, and M. Takigawa. 2000. Percutaneous peptide immunization via corneum barrier-disrupted murine skin for experimental tumor immunoprophylaxis. *Proc. Natl. Acad. Sci. USA* 97:371-376.
18. Shi, Z., D. T. Curiel, and D. C. Tang. 1999. DNA-based non-invasive vaccination onto the skin. *Vaccine* 17:2136-2141.
19. Swain, S. L., H. Hu, and G. Huston. 1999. Class II-independent generation of CD4 memory T cells from effectors. *Science* 286:1381-1383.
20. Tang, D. C., R. S. Jennelle, Z. Shi, R. I. Garver, Jr., D. P. Carbone, F. Loya, C.-H. Chang, and D. T. Curiel. 1997. Overexpression of adenovirus-encoded transgenes from the cytomegalovirus immediate early promoter in irradiated tumor cells. *Hum. Gene Ther.* 8:2117-2124.
21. Tang, D. C., S. A. Johnston, and D. P. Carbone. 1994. Butyrate-inducible and tumor-restricted gene expression by adenovirus vectors. *Cancer Gene Ther.* 1:15-20.
22. Tang, D. C., Z. Shi, and D. T. Curiel. 1997. Vaccination onto bare skin. *Nature* 388:729-730.
23. Udwadia, F. E. (ed.). 1994. Tetanus. Oxford, New York, N.Y.
24. Ulmer, J. B., J. J. Donnelly, S. E. Parker, G. H. Rhodes, P. L. Felgner, V. J. Dwarki, S. H. Gromkowski, R. R. Deck, C. M. DeWitt, A. Friedman, L. A. Hawe, K. R. Leander, D. Martinez, H. C. Perry, J. W. Shiver, D. L. Montgomery, and M. A. Liu. 1993. Heterologous protection against influenza by injection of DNA encoding a viral protein. *Science* 259:1745-1748.
25. Wickham, T. J., E. Tzeng, L. L. Shears, P. W. Roelvink, Y. Li, G. M. Lee, D. E. Brough, A. Lizonova, and I. Kovacs. 1997. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. *J. Virol.* 71:8221-8229.
26. Wolff, J. A., J. J. Ludtke, G. Acsadi, P. Williams, and A. Jani. 1992. Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. *Hum. Mol. Genet.* 1:363-369.
27. Xiang, Z. Q., Y. Yang, J. M. Wilson, and H. C. J. Ertl. 1996. A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. *Virology* 219:220-227.
28. Zeng, M., S. K. Smith, F. Siegel, Z. Shi, K. R. Van Kampen, C. A. Elmetts, and D. C. Tang. 2001. AdEasy system made easier by selecting the viral backbone plasmid preceding homologous recombination. *BioTechniques* 31: 260-262.
29. Zinkernagel, R. M., and H. Hengartner. 2001. Regulation of the immune response by antigen. *Science* 293:251-253.

Benchmarks

American Heart Association. Transgenic mice were generated and maintained at the University of Iowa Transgenic Animal Facility, which is supported in part by the College of Medicine and the Diabetes and Endocrinology Research Center. DNA sequencing was performed at the University of Iowa DNA Core Facility. Requests for materials should be addressed to Curt D. Sigmund at curt-sigmund@uiowa.edu. Address correspondence to Dr. Curt D. Sigmund, Chair, Molecular Biology Interdisciplinary Program, Director, Transgenic and Gene Targeting Facility Department of Internal Medicine and Physiology & Biophysics, 2191 Medical Laboratory, The University of Iowa College of Medicine, Iowa City, IA 52242, USA. e-mail: curt-sigmund@uiowa.edu

Received 8 February 2001; accepted 9 May 2001.

David E. Stec, Satoshi Morimoto, and Curt D. Sigmund
The University of Iowa
College of Medicine
Iowa City, IA, USA

AdEasy System Made Easier by Selecting the Viral Backbone Plasmid Preceding Homologous Recombination


BioTechniques 31:260-262 (August 2001)

Recombinant adenovirus is widely used as a mammalian cell expression vector for multiple purposes including gene therapy (1) and noninvasive vaccination (5). It is urgent at this juncture to develop an efficient protocol for constructing adenovirus recombinants in a timely manner. The conventional approach to construct a replication-defective recombinant adenoviral vector requires a series of time-consuming and labor-intensive steps involving homologous recombination between two transfected plasmids in mammalian packaging cells (3). The finding that homologous recombination can be carried out in *E. coli* (2,4) streamlined the procedure by allowing recombination to occur overnight in bacterial cells and obviated the need for plaque purification. The AdEasy system (4) is one of the fast-track systems for generating recombinant adenovirus by homologous recombination in *E. coli*. Typically, a linearized shuttle vector plasmid encoding kanamycin resistance is mixed with an adenoviral backbone plasmid (pAdEasy-1 or pAdEasy-2) encoding ampicillin resistance, followed by co-transformation into competent *E. coli* BJ5183 cells. Recombinants are subsequently selected for kanamycin resistance and identified by size in conjunction with restriction endonuclease analysis. Finally, recombinant adenoviral vectors are generated by transfecting the recombinant plasmid into a mammalian packaging cell line (e.g., 293 or 911 cells).

We report here that the key step in producing a recombinant plasmid in *E. coli* can be enhanced by pre-selecting the adenoviral backbone plasmid before the delivery of the shuttle vector plasmid. In this two-step transformation protocol, we electroporated an adenoviral backbone plasmid (i.e., pAdEasy-1) into *E. coli* BJ5183 cells,

followed by growing transformants on LB agar plates containing 50 µg/mL ampicillin. A single colony containing pAdEasy-1 (BJ5183pAdEasy-1) was subsequently characterized by restriction analysis of the plasmid. BJ5183pAdEasy-1 cells were made electrocompetent as described (4) and kept in aliquots at -80°C. To trigger a recombination reaction, a shuttle vector plasmid encoding the *Bacillus anthracis* protective antigen (pShuttle-CMV.PA63) was digested with restriction endonuclease *PmeI*, and 25 ng linearized plasmid DNA, without enzyme inactivation and purification, was directly electroporated into BJ5183pAdEasy-1 cells. Transformants were selected on LB agar plates containing 50 µg/mL kanamycin. Plasmid DNA was prepared from individual colonies using the QIAprep® spin miniprep kit (Qiagen, Valencia, CA, USA). The 9.2-kb pShuttle-CMV.PA63 plasmid and the 35-kb recombinant plasmid, both selectable by kanamycin resistance, could be clearly identified by size after fractionating supercoiled DNA in agarose gel.

As shown in Figure 1, transformation by mixing pShuttle-CMV.PA63 with pAdEasy-1 before electroporation as described (4) resulted in a success rate of 12% (2/17), whereas the new two-step transformation protocol generated recombinant plasmids at a frequency of 94% (16/17). The difference in outcomes between the two protocols was highly significant ($P < 0.001$ by Fisher's exact test). BJ5183pAdEasy-1 competent cells that had been frozen at -80°C for up to eight months were as efficient as their freshly prepared counterparts in generating recombinant plasmids. We envision that the enhanced selection of recombinants in antibiotics following two-step transformation may be attributed to productive recombination between incoming shuttle vector plasmids and pre-selected pAdEasy-1 plasmids that existed as autonomous replicons in *E. coli* cells. It is conceivable that only a small fraction of the pAdEasy-1 plasmid pool may be allowed to persist in *E. coli* cells following transformation because there is a high chance for a large plasmid [pAdEasy-1 is 33 kb in size (4)] to be defective (e.g., nicks along its long DNA strands), and/or the efficiency for



DNA Sequencing
PUBLICATION QUALITY
Let us help you increase your productivity.
Immediately.

- Single Run
- Double-Strand
- Single-Strand
- Since 1989

Call 1-800-697-8685 or
e-mail: info@sequetech.com

Sequetech
Visit us at www.sequetech.com

Benchmarks

connecting a large plasmid to the cellular replication machinery may be low. Therefore, homologous recombination between a shuttle vector plasmid and an adenoviral backbone plasmid unable to exist as a replicon in *E. coli* cells is counterproductive for generating selectable recombinant plasmids because such recombinants are abortive. The two-step transformation protocol en-

sures that homologous recombination occurs in a productive manner by eliminating defective and non-replicative adenoviral backbone plasmids in advance, thereby allowing a higher success rate during the selection for recombinants. Moreover, the step to inactivate *PmeI* with phenol/chloroform and purify the linearized shuttle vector plasmid as described (4) is no

longer required because the need to mix the linearized shuttle vector plasmid with the supercoiled adenoviral backbone plasmid before transformation is negated. Overall, this two-step transformation protocol may have broad utility in systems that involve homologous recombination in bacteria.

REFERENCES

1. Benihoud, K., P. Yeh, and M. Perricaudet. 1999. Adenovirus vectors for gene delivery. *Curr. Opin. Biotechnol.* 10:440-447.
2. Chartier, C., E. Degryse, M. Gantzer, A. Dieterle, A. Pavirani, and M. Mehtali. 1996. Efficient generation of recombinant adenovirus vectors by homologous recombination in *Escherichia coli*. *J. Virol.* 70:4805-4810.
3. Graham, F.L. and L. Prevec. 1995. Methods for construction of adenovirus vectors. *Mol. Biotechnol.* 3:207-220.
4. He, T.C., S. Zhou, L.T. da Costa, J. Yu, K.W. Kinzler, and B. Vogelstein. 1998. A simplified system for generating recombinant adenoviruses. *Proc. Natl. Acad. Sci. USA* 95:2509-2514.
5. Tang, D.C., Z. Shi, and D.T. Curiel. 1997. Vaccination onto bare skin. *Nature* 388:729-730.

The AdEasy system was provided by Drs. Tong-Chuan He and Bert Vogelstein at the Johns Hopkins University. The Bacillus anthracis protective antigen gene was provided by Drs. Joanne McAndrew and Charles Turnbough, Jr. at the University of Alabama at Birmingham. Address correspondence to Dr. De-chu C. Tang, Department of Dermatology, University of Alabama at Birmingham, VH-501, 1670 University Blvd., Birmingham, AL 35294-0019, USA. e-mail: dctang@uab.edu

Received 13 March 2001; accepted 9 May 2001.

M. Zeng^{1,2}, S.K. Smith¹,
F. Siegel¹, Z. Shi¹, K.R. Van
Kampen¹, C.A. Elmets², and
D.C. Tang^{1,2}

¹Vaxin, Inc.

²University of Alabama at
Birmingham
Birmingham, AL, USA

For reprints of this or
any other article, contact
Reprints@BioTechniques.com




Figure 1. Enhanced generation of selectable plasmid recombinants following homologous recombination in *E. coli* cells by pre-selecting the adenoviral backbone plasmid. Homologous recombination between the pShuttle-CMV.PA63 plasmid (9.2 kb) and the pAdEasy-1 plasmid (33 kb) in *E. coli* BJ5183 cells was triggered by two different protocols: (i) a one-step transformation protocol by which the two plasmids were mixed before electroporation as described (4) and (ii) a two-step transformation protocol that allows the linearized pShuttle-CMV.PA63 plasmid to be transformed into *E. coli* BJ5183pAdEasy-1 cells harboring the pAdEasy-1 plasmid as a pre-selected autonomous replicon. Lane M, molecular weight marker (*HindIII*-cleaved λ DNA) (Life Technologies, Rockville, MD, USA); lane A, supercoiled pAdEasy-1 DNA control; lane B, supercoiled pShuttle-CMV.PA63 DNA control; lanes 1-34, supercoiled plasmid DNA from individual kanamycin-resistant colonies following homologous recombination using either the one-step transformation protocol (lanes 1-17) or the two-step transformation protocol (lanes 18-34). DNA samples were fractionated in 0.8% agarose gel, stained with ethidium bromide, and visualized with the Gel-Doc™ 2000 (Bio-Rad Laboratories, Hercules, CA, USA).

DNA-based non-invasive vaccination onto the skin

Zhongkai Shi^{a, b, c, d}, David T. Curiel^{a, b, c, d}, De-chu Tang^{a, b, c, d, e, *}

^a*Vaxin Pharmaceuticals, Inc., Birmingham, AL 35209, USA*

^b*Gene Therapy Center, University of Alabama at Birmingham, THT 215, 1900 University Blvd., Birmingham, AL 35294, USA*

^c*Department of Medicine, University of Alabama at Birmingham, THT 215, 1900 University Blvd., Birmingham, AL 35294, USA*

^d*Division of Pulmonary and Critical Care Medicine, University of Alabama at Birmingham, THT 215, 1900 University Blvd., Birmingham, AL 35294, USA*

^e*Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, THT 215, 1900 University Blvd., Birmingham, AL 35294-0006, USA*

Received 21 May 1998; received in revised form 3 December 1998; accepted 4 December 1998

Abstract

Non-invasive vaccination onto the skin (NIVS) could improve vaccination programs because the procedure requires no specially trained personnel and may eliminate many problems associated with needle injections. There is also evidence that the efficacy of a skin-targeted vaccine may be optimal when the antigen is expressed within the outer layer that is in constant contact with potential pathogens. We report here that non-invasive gene delivery by pipetting adenovirus- or liposome-complexed plasmid DNA onto the outer layer of skin could achieve localized transgene expression within a restricted subset of skin in mice and the elicitation of an immune response against the protein encoded by the DNA. These results provide a proof of principle that NIVS may appear as a novel method for the administration of DNA-based vaccines. © 1999 Elsevier Science Ltd. All rights reserved.

Keywords: DNA-based vaccine; Non-invasive vaccine; Skin-targeted vaccine

1. Introduction

Vaccination usually requires needle injections by medical personnel. Non-invasive vaccination onto the skin (NIVS) by expressing antigens in the outer layer of skin [1] not only may allow the administration of vaccines by individuals without medical training or equipment, but may also elicit more potent immune responses than conventional needle injections given equivalent doses due to the immunocompetence of epidermis along the skin border [2]. We report here that NIVS using DNA-based expression vectors was able

to elicit a systemic immune response against the protein encoded by the vector. Unlike inoculation of DNA-based vaccines using a gene gun [3] or a needle [4], the procedure is non-invasive and requires no special skill or equipment. In contrast to NIVS using adenovirus (Ad) recombinants [1], construction and preparation of recombinant plasmid DNA is technically less demanding. Re-vaccination by DNA-based vaccines is also possible [3]. Although NIVS using protein-based vaccines has recently been demonstrated [5], DNA-based vaccines can be purified at lower costs than their protein-based counterparts, and may be able to stimulate a broader spectrum of immune responses for achieving greater efficacy similar to natural infections [6].

* Corresponding author. Tel.: +1-205-975-5603; fax: +1-205-975-0455; e-mail: tang@vaxin.com.

2. Materials and methods

2.1. Cell cultures

Human 293 cells for the propagation of AdCMV-luc [7] were cultured in RPMI medium 1640. W162 cells for the propagation of Ad dl1014 [8] were cultured in DMEM/F12 medium. All media contained 2% fetal bovine serum and 6% calf serum.

2.2. Preparation of DNA/Ad and DNA/liposome complexes

DNA/Ad complexes were prepared by mixing 100 µg plasmid DNA to 1×10^{11} particles of Ad dl1014 for each inoculation. Ad particles were chemically linked to polylysine as described [9] before reacting with DNA. The DNA/Ad complex was further condensed with polylysine. The titer of Ad was determined by absorbance as described [10]. DNA/liposome complexes were prepared by mixing 100 µg plasmid DNA with 100 µg DOTAP/DOPE (1:1; Avanti) for each inoculation. Plasmids were prepared using Qiagen Plasmid Maxi Kits.

2.3. Skin-targeted non-invasive gene delivery

Mice (C57BL/6 strain; 3–8 months old; Jackson) were anesthetized and hair covering a restricted area of neck skin was removed with a WAHL cordless trimmer (Model 8900). The shaved skin was further treated with a depilatory (e.g. Nair) which potentially may facilitate the removal of more cornified epithelium. Ad recombinants, DNA/Ad complexes or DNA/liposome complexes were pipetted into a plastic cylinder (made by drilling a hole through the cap of a Nalgene cryogenic vial) that was glued onto the pre-shaved neck of a mouse. Expression vectors were allowed to incubate with naked skin for 1–18 h. Animal care was in accordance with institutional guidelines.

2.4. Luciferase assay

A piece of excised skin was homogenized and luciferase activity in the skin extract was determined with a luminometer by measurement of integrated light emission for 2 min using the Promega's luciferase assay system.

2.5. Western blot analysis

Sera from tail bleeds were diluted 1:250 and reacted with purified human growth hormone protein (hGH) (CalBiochem) that had been separated in a 12% SDS-polyacrylamide gel and transferred to an Immobilon-P membrane (Millipore) as described [1].

2.6. ELISA for quantitating anti-hGH antibodies

Titers of anti-hGH IgG were determined by ELISA as described [11] using purified hGH as the capture antigen. Serum samples and peroxidase-conjugated goat anti-mouse IgG (Promega) were incubated sequentially on the plates for 1 h at RT with extensive washing between each incubation. The serum samples were diluted in 10-fold increments. The end-point titer was calculated as the dilution of serum producing the same OD₄₉₀ as a 1/100 dilution of preimmune serum.

3. Results

3.1. Skin-targeted non-invasive gene delivery

As an initial step for the development of DNA-based NIVS, we expressed exogenous genes in the skin of mice by pipetting DNA/Ad or DNA/liposome complexes onto naked skin. As shown in Fig. 1, minute amounts of luciferase could be produced in the skin after incubating naked skin with AdCMV-luc particles (an adenovirus vector encoding luciferase driven by the human cytomegalovirus (CMV) promoter) [7], pVR 1216 DNA (a plasmid expression vector encoding luciferase driven by the CMV promoter) complexed with the E4-defective Ad dl1014 [8] or pVR-1216 DNA complexed with DOTAP/DOPE liposomes. No luciferase was detectable in internal organs (e.g. muscle, liver, spleen, heart, lung and kidney) after topical application of expression vectors. The level of transgene expression from Ad recombinants in the skin was on average higher than that from DNA/Ad complexes, which was higher than that from DNA/liposome complexes. The amount of protein produced may potentially be amplified by incubating more vectors with a larger area of skin for a longer period of time. Topical application of pVR-1216 DNA alone without complexing to Ad particles or liposomes produced no measurable luciferase activity in the skin.




Fig. 1. Skin-targeted non-invasive gene delivery. Mice were inoculated with expression vectors encoding luciferase in a non-invasive mode as described in Section 2. The treated skin was removed at the end of the 18-h incubation period, homogenized and assayed for luciferase activity and background was subtracted from the readings. Mice mock-inoculated or inoculated with DNA alone produced no detectable luciferase activity in the skin. LU, light units; Ad, AdCMV-luc; DNA/Ad, pVR-1216 DNA complexed with Ad dl1014; DNA/liposome, pVR-1216 DNA complexed with DOTAP/DOPE. Results are the mean $\log[\text{LU per cm}^2 \text{ skin}] \pm \text{S.E.}$ (n is shown on top of each column).

3.2. DNA-based NIVS

The expression of transgenes in the skin from topically-applied DNA/Ad or DNA/liposome complexes suggests that these complexes may be formulated as components in skin-targeted non-invasive vaccines. To determine whether the amount of antigen produced in the skin from a topically-applied vector was sufficient for eliciting an immune response, an expression plasmid encoding hGH (pCMV-GH) [3] was complexed with either Ad dl1014 or DOTAP/DOPE liposomes. Mice were subsequently vaccinated by incubating DNA/Ad or DNA/liposome complexes with a restricted subset of pre-shaved skin for 1–18 h. Only a small fraction of vectors could be absorbed by the skin as shown by the ability to retrieve most DNA from the skin surface an hour after incubation. No physical abrasions were found in the skin tissue after incubation, and there was no inflammation associated with the treated skin. Immunized animals were subsequently monitored for the production of antibodies against hGH by assaying sera from tail-bleeds. A month after incubating DNA with naked skin, the test sera from representative mice could react in western blots with purified hGH, but not with bovine serum albumin (BSA) (Fig. 2). Pre-immunization sera, sera from untreated animals and sera from animals vaccinated with irrelevant vectors all failed to react with hGH. Of

7 mice vaccinated by DNA/Ad complexes, all (100%) produced antibodies against hGH within 7 months (Table 1). Of 12 mice vaccinated by DNA/liposome complexes, all (100%) treated animals produced antibodies against hGH (Table 1). The possibility of oral vaccination by ingesting DNA complexes through grooming was eliminated by cleaning the neck skin after removing the DNA-containing cylinder and by mixing naive and vaccinated animals in the same cages. No cross-vaccination between naive and vaccinated mice was ever observed.

The titer of antibodies induced by topical application of DNA/Ad complexes was about 10-fold lower than that elicited by intramuscular injection (IM) of 50 μg of pCMV-GH DNA (Table 1). ELISA showed that DNA/liposome complexes were even less potent than DNA/Ad complexes for eliciting an immune response (Table 1), probably due to the low efficiency of skin-targeted gene delivery (Fig. 1). To demonstrate the feasibility that DNA-based vaccines could re-vaccinate animals in a non-invasive mode, we incubated naked skin of 3 naïve mice with DNA/Ad complexes containing Ad dl1014 complexed with irrelevant plasmid DNA (e.g. pGT37 DNA [12]). As shown in Table 1, antibodies against hGH were still induced when animals with pre-exposure to Ad dl1014 were immunized 9 weeks later by topical application of pCMV-GH DNA/Ad complexes.

4. Discussion

Vaccinating animals or humans by delivering DNA-based vaccines onto the outer layer of skin in a non-invasive mode is an appealing strategy provided that extrinsic antigens can be expressed in viable cells in the authentic skin tissue environment in sufficient quantities for eliciting immunity. We have shown that the production of very small amounts of protein in the skin (Fig. 1) was sufficient for eliciting a systemic immune response (Table 1 and Fig. 2) which may have arisen as a result of antigen expression in a limited number of cells *in vivo*. The amount of DNA absorbed by the skin during incubation has not been quantitatively measured although it must be small as reflected by the amount of protein produced and the ability to retrieve most DNA from the skin surface. It has been determined that a humoral immune response can be elicited in a mouse by inoculating 40 ng of plasmid DNA into the skin using a gene gun and a cellular immune response can be induced with 0.4 ng of plasmid DNA [13]. Because a fraction of the DNA may be scraped off gold microprojectiles




Fig. 2. (a) DNA/Ad-mediated NIVS. Serum from a mouse vaccinated by topical application of pCMV-GH DNA/Ad complexes was analyzed for the presence of anti-hGH antibodies by western blot analysis. Lane 1, hGH (1 μ g); lane 2, BSA (1 μ g); lane 3, Ad dl1014 (10^{10} particles). (b) DNA/liposome-mediated NIVS. Serum from a mouse vaccinated by topical application of pCMV-GH DNA/liposome complexes was analyzed for the presence of anti-hGH antibodies. Lane 1, hGH (1 μ g); lane 2, BSA (1 μ g). Animals were immunized by NIVS and western blots were analyzed as described in Section 2.

during a flight when DNA is inoculated into tissues with a gene gun, the minimal amount of DNA that is required for eliciting humoral and cellular immune responses by expressing antigens in the skin may be even less than 40 and 0.4 ng, respectively. The minute amount of DNA that is required for vaccinating an animal via the skin route highlights the immunocom-

petence of the outer layer of skin and the safety of DNA-based NIVS.

Expression vectors applied onto the skin in a non-invasive mode presumably could penetrate into the body via hair follicles, sweat ducts or minor breaches in the skin. The principal target cells for topically-applied vectors have been identified utilizing either an

Table 1
Summary of the immune responses in mice following DNA-based vaccination

Vector ^a	Pre-exposure to Ad	Mode	Weeks post-immunization	Number of boost	Number of mice producing anti-GH	Anti-hGH IgG serum titer
DNA/Ad	–	NIVS	28	0	2/2	1,000
DNA/Ad	–	NIVS	14	2	5/5	1,000–10 000
DNA/liposome	–	NIVS	28	0	2/2	1,000
DNA/liposome	–	NIVS	22	3	10/10	1,000
DNA	–	IM	12	0	4/4	10,000–100 000
DNA/Ad ^b	+	NIVS	37	1	3/3	10 000

^a C57 BL/6 mice were immunized by NIVS or IM injection of DNA. DNA/Ad, pCMV-GH DNA complexed with Ad dl1014; DNA/liposome, pCMV-GH DNA complexed with DOTAP/DOPE; DNA, 50 μ g pCMV-GH DNA dissolved in saline (1 mg/ml) was injected into the tongue muscle of an anesthetized mouse. ^b Mice were exposed to Ad by topical application of Ad dl1014 complexed with irrelevant DNA (e.g. pGT37 DNA [12]) as described in Section 2. Nine weeks later, animals with pre-exposure to Ad were immunized by non-invasive vaccines containing pCMV-GH DNA complexed with Ad dl1014.

Ad vector encoding β -galactosidase [14] or liposome-complexed plasmid DNA encoding β -galactosidase [15, 16]. Cells within hair follicles [14–16], interfollicular keratinocytes within epidermis [14, 15], as well as dermal fibroblasts [15] appeared as target cells for topically-applied expression vectors. Although the target cells for topically-applied DNA/Ad complexes have not been studied, it is conceivable that they are identical to those transduced by Ad vectors since the tropism of the DNA/Ad complex should be mediated by Ad particles within the complex. Consistent with our finding that no luciferase expression was detected in internal organs including the muscle layer underlying the treated skin, the absence of β -galactosidase-positive muscle cells [14–16] suggests that this non-invasive mode of gene delivery may limit transgene expression within the skin. However, the ability to vaccinate animals by NIVS implies that specific peptide fragments of the exogenous antigens produced in the outer layer of skin may be acquired by professional antigen-presenting cells (APCs) that are able to relocate to lymphoid organs or other sites in the body. Alternatively, a small number of APCs may be directly transfected by topically-applied vectors. Identification and characterization of these putative APCs may provide insights into the mechanisms of NIVS.

The possibility that animals may have been immunized by orally ingesting DNA has been eliminated as described above. It is unlikely that DNA (in the format as described in this report) can immunize animals orally by resisting digestive enzymes found in the gastrointestinal tract. In contrast to the hostile environment that oral vaccines encounter before they battle against pathogens, the skin surface is less destructive to biomolecules. Absorption of DNA by the skin may thus allow epidermal vaccines to be formulated with less sophistication than their oral counterparts. In future vaccination programs, it is conceivable that NIVS and other modes of immunization may complement each other because vaccination via different routes may elicit different immune responses by different mechanisms.

The E1-defective Ad vectors may not be able to vaccinate animals repeatedly as vaccine carriers, attributed to the immunogenicity of Ad vectors which impair Ad-mediated gene expression in animals with pre-existing immunity to Ad [17]. DNA/liposome complexes which do not contain any antigenic components other than the antigen encoded by the DNA should allow continued re-vaccination. It is promising that DNA/Ad complexes containing Ad vectors with reduced immunogenicity (e.g. E4-defective Ad [8], 'gutless' Ad

with viral genes deleted [18] or UV-inactivated Ad [10]) will allow re-vaccination or the induction of immune reactivity in animals with pre-exposure to Ad. Given the high skin-targeted transfection efficiency of DNA/Ad complexes when compared to that of DNA/liposome complexes (Fig. 1), a higher antibody titer induced by non-invasive delivery of DNA/Ad complexes over that elicited by their liposome counterparts (Table 1), a persistent wave of *in vivo* transgene expression from either E4-defective Ad [19] or 'gutless' Ad [20] in immunocompetent animals and the ability to immunize animals with pre-exposure to Ad by DNA/Ad complexes (Table 1), it is likely that DNA/Ad complexes may be able to consolidate the high efficiency of Ad for *in vivo* gene delivery, the ease with plasmid manipulation and the ability to re-vaccinate animals into one formula for the development of skin-targeted non-invasive vaccines.

Although IM injection of DNA could elicit a more potent immune response than DNA-based NIVS (Table 1), the amount of DNA absorbed by the skin during NIVS was probably only a small fraction of that injected into muscle. NIVS is thus potentially safer than injection of a large dose of DNA into deep tissues. It is conceivable that the efficacy of DNA-based NIVS may be improved by (1) covering a large area of skin for a long period of time, (2) developing a new generation of skin-targeted vectors with a higher *in situ* transfection efficiency and (3) developing specific adjuvants for NIVS. In contrast to IM injection of pCMV-GH DNA which is capable of eliciting an immune response, intradermal injection of naked DNA appeared as an ineffective vaccination mode for this specific vector [3]. Although direct comparisons between topically-applied DNA/Ad or DNA/liposome complexes and their intradermally-injected counterparts have not been made, it was reported that the deeper the DNA was inoculated into the skin, the less potent the vaccine was [2]. Animals may have evolved an immune surveillance mechanism within epidermis for warding off potential infections along the skin border. We hypothesize that the expression of antigens in a small number of cells within the outer layer of skin can activate the surveillance mechanism and subsequently result in an immune response against the antigen encoded by the vector.

The immunologic competence of the skin, the ease with which genes can be targeted to defined sites on the skin, the rapid turn-over of skin cells, the efficacy of DNA-based vaccines and our finding that animals can be immunized by DNA-based NIVS, may allow for the development of a unique method for vaccination. We envision that skin-targeted non-invasive

vaccines could be delivered by a patch containing a uniform dose of DNA. Since DNA-based NIVS is simple, economical, painless and potentially safe, it may be able to boost vaccine coverages in a wide variety of disease settings.

Acknowledgements

We thank M. Alder and R. Young for their support; A. Graf, E. Sorscher and A. LoBuglio for critical reading of the manuscript; D. Marks, S. Johnston, T. Strong, A. Takashima and M. Olman for lively discussion and Vical for providing the plasmid pVR-1216. This work was supported by a UAB start-up fund, an ALA grant, a US Army idea award and a NIH SBIR grant to D.T. Z.S. was supported by the World Health Organization and the Emerging Technology Partners.

References

- [1] Tang D-c, Shi Z, Curiel DT. Vaccination onto bare skin. *Nature* 1997;388:729–30.
- [2] Eisenbraun MD, Fuller DH, Haynes JR. Examination of parameters affecting the elicitation of humoral immune responses by particle bombardment-mediated genetic immunization. *DNA Cell Biol.* 1993;12:791–7.
- [3] Tang D-c, DeVit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. *Nature* 1992;356:152–4.
- [4] Ulmer JB, Donnelly JJ, Parker SE et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. *Science* 1993;259:1745–8.
- [5] Glenn GM, Rao M, Matyas GR, Alving CR. Skin immunization made possible by cholera toxin. *Nature* 1998;391:851.
- [6] McDonnell WM, Askari FK. DNA vaccines. *N. Engl. J. Med.* 1996;334:42–5.
- [7] Tang D-c, Jennelle RS, Shi Z et al. Overexpression of adenovirus-encoded transgenes from the cytomegalovirus immediate early promoter in irradiated tumor cells. *Human Gene Ther.* 1997;8:2117–24.
- [8] Scaria A, Curiel DT, Kay MA. Complementation of a human adenovirus early region 4 deletion mutant in 293 cells using adenovirus-polylysine-DNA complexes. *Gene Ther.* 1995;2:295–8.
- [9] Nguyen DM, Wiehle SA, Roth JA, Cristiano RJ. Gene delivery into malignant cells in vivo by a conjugated adenovirus/DNA complex. *Cancer Gene Ther.* 1997;4:183–90.
- [10] Cotten M, Wagner E, Zatloukal K, Phillips S, Curiel DT, Birnstiel ML. High-efficiency receptor-mediated delivery of small and large (48 kilobase) gene constructs using the endosome-disruption activity of defective or chemically inactivated adenovirus particles. *Proc. Natl. Acad. Sci. USA* 1992;89:6094–8.
- [11] Deck RR, DeWitt CM, Donnelly JJ, Liu MA, Ulmer JB. Characterization of humoral immune responses induced by an influenza hemagglutinin DNA vaccine. *Vaccine* 1997;15:71–8.
- [12] Conry RM, LoBuglio AF, Loechel F et al. A carcinoembryonic antigen polynucleotide vaccine for human clinical use. *Cancer Gene Ther.* 1995;2:33–8.
- [13] Johnston SA, Barry MA. Genetic to genomic vaccination. *Vaccine* 1997;15:808–9.
- [14] Lu B, Federoff HJ, Wang Y, Goldsmith LA, Scott G. Topical application of viral vectors for epidermal gene transfer. *J. Invest. Dermatol.* 1997;108:803–8.
- [15] Alexander MY, Akhurst RJ. Liposome-mediated gene transfer and expression via the skin. *Human Mol. Genet.* 1995;4:2279–85.
- [16] Li L, Hoffman RM. The feasibility of targeted selective gene therapy of the hair follicle. *Nature Med.* 1995;1:705–6.
- [17] Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. *Proc. Natl. Acad. Sci. USA* 1994;91:4407–11.
- [18] Parks RJ, Chen L, Anton M, Sankar U, Rudnicki MA, Graham FL. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. *Proc. Natl. Acad. Sci. USA* 1996;93:13565–70.
- [19] Wang Q, Greenburg G, Bunch D, Farson D, Finer MH. Persistent transgene expression in mouse liver following in vivo gene transfer with a delta E1/delta E4 adenovirus vector. *Gene Ther.* 1997;4:393–400.
- [20] Chen HH, Mack LM, Kelly R, Ontell M, Kochanek S, Clemens PR. Persistence in muscle of an adenoviral vector that lacks all viral genes. *Proc. Natl. Acad. Sci. USA* 1997;94:1645–50.

De-chu Christopher Tang, Ph.D.

**Scientific Founder, Vice President and Chief Technical Officer
Vaxin, Inc.**

**Research Associate Professor
University of Alabama at Birmingham
Department of Dermatology
Gene Therapy Center
Comprehensive Cancer Center**

**VH-501
1670 University Boulevard
Birmingham, Alabama 35294-0019**

**Phone: 205-975-5603
Fax: 205-975-0455
Email: dctang@uab.edu**

Professional Employment

2001-Present	Research Associate Professor University of Alabama at Birmingham Birmingham, Alabama
1997-Present	Vice President and Chief Technical Officer Vaxin, Inc. Birmingham, Alabama
1994-2001	Research Assistant Professor University of Alabama at Birmingham Birmingham, Alabama
1992-1994	Instructor Dr. David P. Carbone's laboratory University of Texas Southwestern Medical Center Dallas, Texas
1991-1992	Assistant Instructor Dr. Stephen A. Johnston's laboratory University of Texas Southwestern Medical Center Dallas, Texas

- 1990-1991 Research Associate
Dr. Stephen A. Johnston's laboratory
Duke University
Durham, North Carolina
- 1988-1990 Research Associate
Dr. Gretchen J. Darlington's laboratory
Baylor College of Medicine
Houston, Texas

Education

- 1989 Ph.D. in Microbiology and Molecular Biology
Dr. Milton W. Taylor's laboratory
Indiana University
Bloomington, Indiana
- 1976 M.S. in Animal Physiology
Tunghai University
Taichung, Taiwan
- 1974 B.S. in Biology
Tunghai University
Taichung, Taiwan

Memberships

American Society of Gene Therapy (ASGT #: fCy40XC)
American Association for Cancer Research (AACR #: 10889)
American Association for the Advancement of Science (AAAS#: 02231980)
Society of Chinese Bioscientists in America

Invited and Selected Lectures

Noninvasive vaccination onto the skin. *Kiwanis Club*. Birmingham, Alabama, April 24, 2001.

Skin-targeted noninvasive vaccination against mammary tumor cells. *Era of Hope Department of Defense Breast Cancer Research Program Meeting*. Atlanta, Georgia, June 11, 2000

Analysis of target cells following vector-based noninvasive vaccination onto the skin. *The Third Annual Meeting of The American Society of Gene Therapy*. Denver, Colorado, June 3, 2000

Skin-targeted noninvasive vaccination. *National Vaccine Advisory Committee*. Washington, D.C., May 22, 2000

Skin-targeted non-invasive vaccine patches. *2000 Annual Meeting of the Society for Investigative Dermatology*. Chicago, Illinois, May 13, 2000

Skin-targeted noninvasive influenza vaccines. *Second Annual Meeting of the American Society of Gene Therapy*. Washington, DC, June 10, 1999

Gene painting as a simple method for eliciting an antitumor immune response. *Sixth International Conference on Gene Therapy of Cancer*. San Diego, California, November 22, 1997

Vaccination by painting genetic vaccines onto the skin. *Second National Symposium on Basic Aspects of Vaccines*. Bethesda, Maryland, April 30, 1997

Vaccination by painting genetic vectors onto skin. *Fifth International Conference on Gene Therapy of Cancer*. San Diego, California, November 15, 1996

Cancer immunotherapy by the B7-1 gene in conjunction with radiotherapy. *Fifth International Conference on Gene Therapy of Cancer*. San Diego, California, November 14, 1996

Adenovirus-mediated cancer gene therapy in conjunction with ionizing radiation and butyrate infusion. *1995 American Thoracic Society International Conference*. Seattle, Washington, May 20, 1995

Butyrate-inducible and tumor-restricted gene expression by adenovirus vectors. *Third Annual Texas Triangle Meeting*. Dallas, Texas, March 19, 1994

In vivo and *in vitro* gene transfer into solid tumors by adenovirus vectors and the gene gun. *Second International Conference on Gene Therapy of Cancer*. San Diego, California, November 18, 1993

Awards

Principal Investigator, 2001-2002, *National Institutes of Health Small Business Innovation Research Program Phase I grant* (#1-R43-AI-46198-01A1): "Noninvasive delivery of skin-targeted rabies vaccines", \$100,000

Principal Investigator, 2001-2002, *National Institutes of Health Small Business Innovation Research Program Phase I grant (#1-R43-AI-47558-01A2)*: "Noninvasive delivery of skin-targeted anthrax vaccines", \$100,000

Principal Investigator, 2001-2004, *Office of Naval Research Grant (#N00014-01-1-0945)*: "Vaccination by topical application of recombinant vectored vaccines", \$3,049,000

Principal Investigator, 2001-2002, *National Institutes of Health Small Business Technology Transfer Program Phase II grant (#2-R42-AI/HD-44520-02)*: "Non-invasive delivery of skin-targeted tetanus vaccines", \$282,625 (Renewable for 2002-2003)

Co-Principal Investigator, 2001-2006, *National Institutes of Health R01 grant (#1-R01-NS-43947-01)*: "Alzheimer vaccinations: Noninvasive vaccination by DNA-based vectors", \$1,250,000

Collaborator, 2001, *Department of Defense Small Business Innovation Research Program Phase I grant (#N00014-01-M-0178)*: "Needleless topical administration of dengue DNA vaccine", \$69,000

Award Winner, Year 2000 *Wallace H. Coulter Award for Innovation and Entrepreneurship* (<http://www.coulter.gatech.edu/2000recip.html>), \$100,000

Preceptor, 2000-2001, *Dermatology Foundation Postdoctoral Fellowship*: "Development of a skin-targeted vaccine patch against anthrax", \$25,000

Investment to Vaxin, Inc., 1999-2000, *Paradigm Venture Partners I, L.L.C.*, \$1,000,000

Principal Investigator, 1999-2000, *National Institutes of Health Small Business Technology Transfer Program Phase I grant (#1-R41-AI-44520-01)*: "Non-invasive delivery of skin-targeted tetanus vaccines", \$100,000

Principal Investigator, 1998-1999, *National Institutes of Health Small Business Innovation Research Program Phase I grant (#1-R43-AI-43802)*: "Non-invasive delivery of skin-targeted flu vaccines", \$100,000

Principal Investigator, 1998-2001, *United States Army Medical Research and Materiel Command Breast Cancer Research Program Idea Award (#DAMD 17-98-1-8173)*: "Gene painting as a simple method for vaccinating animals against breast cancer micro-metastases", \$301,350

Investment to Vaxin, Inc., 1997-1999, *Emerging Technology Partners*, \$733,347

Principal Investigator, 1996-1998, *American Lung Association Research Grant (#RG-167-N)*: "Lung cancer immunotherapy by *in situ* delivery of B7 genes", \$50,000

Principal Investigator, 1994, *University of Alabama at Birmingham Start-Up Fund*, \$300,000

Award Winner, Year 1994 *American Association for Cancer Research Young Investigator Travel Grant*, \$500

Reviewer for Scientific Journals

Ad Hoc Reviewer, *BioTechniques*

Ad Hoc Reviewer, *Gene Therapy*

Ad Hoc Reviewer, *Human Gene Therapy*

Patents

Allowance of the U.S. patent "Vaccination by topical application of genetic vectors" (Filed on 08/13/97; U.S. Serial No. 09/402,527)

"Noninvasive genetic immunization, expression products therefrom, and uses thereof" (Filed on 05/03/99; PCT publication No. WO 00/66179)

[Redacted]

PII Redacted

[Redacted]

Publications

Shi Z, Zeng M, Yang G, Siegel F, Cain LJ, Van Kampen KR, Elmets CA, and **Tang DC**. 2001. Protection against tetanus by needle-free inoculation of adenovirus-vectored nasal and epicutaneous vaccines. *J. Virol.* (in press).

Zeng M, Smith SK, Siegel F, Shi Z, Van Kampen KR, Elmets CA, and **Tang DC**. 2001. AdEasy system made easier by selecting the viral backbone plasmid preceding homologous recombination. *BioTechniques* 31: 260-262.

Shi Z, Curiel DT, and **Tang DC**. 1999. DNA-based non-invasive vaccination onto the skin. *Vaccine* 17: 2136-2141.

Tang DC, Shi Z, and Curiel DT. 1997. Vaccination onto bare skin. *Nature* 388: 729-730.

Tang DC, Jennelle RS, Shi Z, Garver RI, Jr., Carbone DP, Loya F, Chang C-h, and Curiel DT. 1997. Overexpression of adenovirus-encoded transgenes from the cytomegalovirus immediate early promoter in irradiated tumor cells. *Hum. Gene Ther.* 8: 2117-2124.

Dion LD, Goldsmith KT, **Tang DC**, Engler JA, Yoshida M, and Garver RI, Jr. 1997. Amplification of recombinant adenoviral transgene products occurs by inhibition of histone deacetylase. *Virology* 231: 201-209.

Tang DC, Gazdar AF, and Carbone DP. 1996. *In vivo* cytotoxicity assay for assessing immunity. *J. Immunol. Methods* 189: 173-182.

Lee C-T, Ciernik IF, Wu S, **Tang DC**, Chen HL, Truelson JM, and Carbone DP. 1996. Increased immunogenicity of tumors bearing mutant p53 and P1A epitopes after transduction of B7-1 via recombinant adenovirus. *Cancer Gene Ther.* 3: 238-244.

Santoso JT, **Tang DC**, Lane SB, Hung J, Reed DJ, Muller CY, Carbone DP, Lucci JA, Miller DS, and Mathis JM. 1995. Adenovirus-based p53 gene therapy in ovarian cancer. *Gynecol. Oncol.* 59: 171-178.

Johnston SA, and **Tang DC**. 1995. Genetic immunization. In *Molecular Biology and Biotechnology*, R. A. Meyers (ed.), New York: VCH Publishers, pp.367-369.

Tang DC, Johnston SA, and Carbone DP. 1994. Butyrate-inducible and tumor-restricted gene expression by adenovirus vectors. *Cancer Gene Ther.* 1: 15-20.

Tang DC, and Johnston SA. 1994. DNA-coated microprojectiles for gene delivery into live animals. In *Gene Therapy: From Laboratory to the Clinic*, K. M. Hui (ed.), Singapore: World Scientific Publishers, pp.162-175.

Johnston SA, and **Tang DC**. 1994. Gene gun transfection of animal cells and genetic immunization. *Meth. Cell Biol.* 43: 353-365.

Tang DC, and Carbone DP. 1993. Potential application of gene therapy to lung cancer. *Semin. Oncol.* 20: 368-373.

Johnston SA, and **Tang DC**. 1993. The use of microparticle injection to introduce genes into animal cells *in vitro* and *in vivo*. *Genet. Eng.* 15: 225-236.

Tang DC, DeVit M, and Johnston SA. 1992. Genetic immunization is a simple method for eliciting an immune response. *Nature* 356: 152-154.

Tang DC, and Taylor MW. 1992. Memory of butyrate induction by the Moloney murine sarcoma virus enhancer-promoter element. *Biochem. Biophys. Res. Comm.* 189: 141-147.

Yeivin A, **Tang DC**, and Taylor MW. 1992. Sodium butyrate selectively induces transcription of promoters adjacent to the MoMSV viral enhancer. *Gene* 116: 159-164.

Tang DC, and Taylor MW. 1990. Transcriptional activation of the adenine phosphoribosyltransferase promoter by an upstream butyrate-induced Moloney murine sarcoma virus enhancer-promoter element. *J. Virol.* 64: 2907-2911.

Taylor MW, Park J, and **Tang DC**. 1989. An analysis of 5' regulatory sequences of the hamster apt gene. *Adv. Exp. Med. Biol.* 253A: 467-473.

Tang DC, and Alexander PS. 1979. The reproductive cycle of the red-bellied tree squirrel (*Callosciurus erythraeus*) in Taiwan. *Tunghai Univ. Biol. Bulletin (in Taiwan)* 20: 1-7.

Tang DC. 1978. The Aswan Dam. *Nature (in Taiwan)* 2: 52-56.

Tang DC. 1977. Cholera toxin. *Science Monthly (in Taiwan)* 8: 18-22.

Lees CY, Briggs DJ, Davis RD, Moore SM, Gordon C, Xiang Z, Ertl HCJ, **Tang DC**, and Fu ZF. Mice immunized on the skin with a recombinant adenovirus expressing rabies virus glycoprotein developed high titers of neutralizing antibodies and were protected against lethal challenge (submitted).